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Type 2 diabetes is a major public health problem that affects over 10% of the US 
adult population. It is associated with substantially increased risks of mortality and 
serious clinical outcomes such as heart disease, stroke, kidney disease and retinopathy.  
Diabetes is defined by hyperglycemia, or elevated glucose concentrations in the blood, 
which are commonly measured by fasting glucose and hemoglobin A1c (HbA1c), but 
these have limitations.  As a result, nontraditional glycemic biomarkers, fructosamine, 
glycated albumin and 1,5-anhydroglucitol (1,5-AG) are gaining interest.  While it is 
established that genetics play a role in type 2 diabetes, fasting glucose, and HbA1c, the 
genetics of fructosamine, glycated albumin, and 1,5-AG have not been well explored.  
This dissertation sought to determine the amount of variation in each biomarker due to 
genetics through heritability estimation, and to determine the specific genetic variants 
associated with each biomarker though genome wide association study (GWAS) analysis, 
multivariate phenotype analysis, and exome sequencing analysis.   
Heritability estimates showed a substantial portion of fructosamine, glycated 
albumin and 1,5-AG variation was due to genetics, which is likely comprised of both 
common and rare variants.  GWAS identified common variants associated with 
fructosamine and glycated albumin including a known diabetes variant and a likely 
nonglycemic variant. Exome sequencing did not identify variants associated with 
fructosamine and glycated albumin, but multivariate phenotype analysis identified a 
potentially interesting region in a gene that alters bilirubin levels that may affect 
fructosamine in a nonglycemic manner.  Exome sequencing identified rare, coding 
variants with large effect size in a glucose transporting gene associated with 1,5-AG 
 iii 
which inform the biology and may impact the clinical interpretation of 1,5-AG.  
Analyzing the genetics of nontraditional glycemic biomarkers of type 2 diabetes has 
increased the understanding of these biomarkers, including their underlying biology, and 
may aid in decisions about their clinical implementation. 
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Chapter 1: Introduction 
 
1.1 Type 2 diabetes is an important public health concern 
Type 2 diabetes is a major public health problem facing the US and countries 
around the world. The current prevalence of diabetes is 10% in the US,1 , similar to the 
age-standardized worldwide prevalence (9% in men, 7.9% in women) and reaches over 
25% in Polynesia and Micronesia, with a high in American Samoa of more than 30%.2  
300 million individuals have been diagnosed with diabetes worldwide, and this number is 
expected to increase to over 550 million by 2030.3   
Diabetes occurs when glucose levels in the blood are elevated (hyperglycemia), 
which is caused by a combination of beta cell failure and insulin resistance.4  In a healthy 
individual, excess glucose in the blood (e.g., as a result of a recent meal) triggers 
pancreatic beta cells to excrete insulin, a hormone which facilitates glucose uptake from 
the blood into tissues such as muscle, liver and fat, where it is either used for energy or 
stored for future use. In an individual with type 2 diabetes, however, pancreatic beta cells 
fail to adequately excrete insulin and/or the glucose-absorbing cells fail to uptake glucose 
in response to insulin (insulin resistance) which results in chronic hyperglycemia.5 
Diabetes leads to major health complications including blindness, loss of limb, kidney 
disease, heart disease, stroke and death.4,6,7  
 
1.2 Environmental and genetic factors increase risk of type 2 diabetes  
Many behavioral and environmental factors affect the risk of type 2 diabetes, 
including obesity, lack of physical activity, age, and race.4  Genetics also plays a role in 
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type 2 diabetes risk. Heritability, or the proportion of variance in diabetes due to genetics, 
has been estimated from 20% to 80%, with the wide range likely due to differences in 
diabetes definitions, populations, heritability estimation methods, sample types (twins vs 
other family members), and sample size.  A recent study combining 7 twin cohorts 
including 34,166 twin pairs estimated heritability of type 2 diabetes to be 72%.8  This 
suggests a substantial genetic role in diabetes risk.8-11 Genome-wide association studies 
(GWAS) and sequencing studies have identified over 100 genetic variants associated 
with diabetes, using diverse and large samples (up to 150,000 individuals).12,13  The 
majority of the variants identified thus far are common (minor allele frequency≥5%) and 
have small effect sizes (Figure 1.1).  All of these variants, however, only account for 
approximately 10% of the heritability of diabetes, indicating that much work is still to be 
done to understand diabetes genetics.12   
 
1.3 Type 2 diabetes results in elevated blood glucose levels, measured by biomarkers 
 The hallmark of type 2 diabetes, hyperglycemia, can be characterized by different 
biomarkers.  The most commonly used clinical biomarkers of hyperglycemia are fasting 
glucose and hemoglobin A1c (HbA1c), both recommended for screening and diagnosis 
by the American Diabetes Association, along with less commonly used oral glucose 
tolerance test.4 Fasting glucose is a measure of glucose concentration in the blood 
following an 8 hour fast and represents glucose levels at a fixed time point. HbA1c is a 
test that measures the percent of hemoglobin in the blood which is glycated. HbA1c is 
formed by a nonenzymatic binding of glucose to hemoglobin contained within red blood 
cells. It represents average blood glucose levels over the previous 2-3 months.14   
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Fasting glucose and HbA1c both have limitations in their abilities to accurately 
reflect diabetes status. Fasting glucose is burdensome on the patient (requiring an 8 hour 
fast), has high pre-analytic variability, moderate intra-individual variability, and can be 
affected by factors such as recent illness, exercise or stress. HbA1c levels may be 
affected by erythrocyte or hemoglobin related factors such as anemia and rare 
hemoglobin variants.15-17   
 
1.4 Nontraditional biomarkers of hyperglycemia may overcome some limitations of 
traditional measures and are of growing clinical interest 
In light of certain limitations of fasting glucose and HbA1c, additional biomarkers 
of hyperglycemia have been proposed for use in diabetes care: fructosamine, glycated 
albumin and 1,5-anhydroglucitol (1,5-AG).14,17  Fructosamine and glycated albumin are 
both ketoamines, formed by nonenzymatic binding of serum protein to glucose.18 
Fructosamine is a measure of the concentration of total serum protein bound to glucose, 
while glycated albumin is a measure of the percent of albumin (the most prevalent serum 
protein) that is glycated. Both represent average blood glucose over the previous 2-3 
weeks.18  1,5-AG is a carbohydrate that is structurally similar to glucose and is consumed 
though certain foods including soybeans, rice, bread and beef.19-21 In normoglycemic 
conditions, 1,5-AG is filtered through the kidney, resulting in stable concentrations in the 
blood. In hyperglycemic conditions above the renal threshold for absorption of glucose 
(≥180 mg/dL), glucose outcompetes 1,5-AG for reabsorption in the kidney, leading to 
lower levels of 1,5-AG in the blood.19-22 1,5-AG represents spikes in blood glucose levels 
occurring in the previous 1-2 weeks.19-21 All three biomarkers are associated with 
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diabetes and diabetes-related outcomes similarly to fasting glucose and HbA1c, and can 
predict diabetes after controlling for fasting glucose or HbA1c.23-32 
While these nontraditional biomarkers are not commonly used clinically in the 
US,15 fructosamine is recommended as an alternative to HbA1c in individuals with 
known erythrocyte disorders by organizations in India, Australia and the UK.17 Glycated 
albumin is regularly used clinically to monitor short-term changes in glycemic control for 
diabetes in China, Japan and South Korea (age-standardized diabetes prevalence in 
women and men >18 years: 7.6%, 9.9%; 5%, 8.4%; 6.7%, 9.3%, respectively)2 and was 
recently cleared by the FDA for clinical use in the US.17,33  
Similar to HbA1c, which is an indirect measure of hyperglycemia, fructosamine 
and glycated albumin also have potential limitations based on the non-glucose dependent 
portion of the molecule.  Factors that affect albumin metabolism and serum protein levels 
such as kidney, liver and thyroid disease are known to alter fructosamine and glycated 
albumin levels.34,35 1,5-AG can be affected by diet and kidney impairment.20   
 
1.5 Genetics of traditional hyperglycemia biomarkers have been well-studied 
The genetics of fasting glucose and HbA1c have been well studied. Multiple 
GWAS including one with over 133,000 participants from the Meta-Analyses of Glucose 
and Insulin-related traits Consortium (MAGIC) found 36 variants associated with fasting 
glucose.36 Additionally, a recent paper incorporating approximately 160,000 samples 
from African, European, and Asian ancestries increased the number of HbA1c loci to 
60.37   
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Interestingly, despite fasting glucose and HbA1c both being measures of 
hyperglycemia, only a small number of the genetic variants associated with these 
biomarkers overlap (Figure 1.2) and the genetic correlation is not strong (r=0.41).38   
This is likely due to the differences in the biology of the biomarkers and the glucose 
states they represent. Wheeler et. Al. determined that 22 of 60 HbA1c variants were 
associated with erythrocytic factors not related to diabetes status but to the erythrocytes 
in which HbA1c resides, while 19 variants were glucose-related “glycemic” variants 
(Figure 1.2).37  In addition, each biomarker represents different aspects of glycemic 
states which may also account for the observed differences: HbA1c reflects average 
blood glucose across 2-3 months, while fasting glucose is a measure of instantaneous 
hepatic glucose output. 
Several studies of HbA1c genetics have shown that nonglycemic genetic variants 
can alter HbA1c levels enough to reclassify diabetes status.37,39,40  The lowered HbA1c 
levels due to nonglycemic genetic factors has the potential to underdiagnose a substantial 
number of people (650,000 African American adults in the US alone by one estimate)37 
screened for diabetes by HbA1c, highlighting the importance of investigating glycemic 
biomarker genetics. 
 
1.6 Little is known of the genetics of nontraditional hyperglycemia biomarkers  
While much work has been done to investigate HbA1c and fasting glucose 
genetics, little is known about the genetics of nontraditional hyperglycemia biomarkers.  
Heritability, has been estimated for 1,5-AG measured using an untargeted assay. This 
study estimated approximately 60% of variation in 1,5-AG was due to genetics.41,42  
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Heritability has not been estimated for 1,5-AG using a targeted assay, however.  We 
recently identified common genetic variants associated with 1,5-AG through a GWAS in 
the Atherosclerosis Risk in Communities (ARIC) Study. Seven loci, five of which were 
novel, in genes involved in glucose transport and carbohydrate metabolism were 
significantly associated with 1,5-AG,43  identifying a potentially important pathway 
involved in diabetes pathophysiology that has not been discovered through genetic 
studies of diabetes or other glycemic biomarkers (Figure 1.3, 1.4).  While this GWAS 
captured common variants associated with 1,5-AG, it was not designed to capture rare 
variants. Because the genetic architecture of these biomarkers is likely comprised of both 
common and rare variants, an important portion of the genetic variants associated with 
1,5-AG has not been investigated.   
Even less is known about the genetics of fructosamine and glycated albumin.  No 
heritability studies, nor studies to identify common or rare variants associated with 
fructosamine and glycated albumin have been done. Given the known clinical impact of 
nonglycemic genetics on the ability of HbA1c to accurately reflect diabetes status, and 
the structure of fructosamine and glycated albumin are similarly impacted by both 
glucose and nonglucose factors, it is imperative to understand the genetics of 
nontraditional markers of hyperglycemia to inform their clinical interpretation.  
 
1.7 Dissertation specific aims 
The purpose of this dissertation was to investigate the genetics of nontraditional 
glycemic biomarkers – fructosamine, glycated albumin and 1,5-AG – and to compare 
them to traditional glycemic biomarkers. 
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This work served two purposes: 
1) to inform the biology of the specific biomarkers under study and potential 
implications for their clinical use; and 
 2) to inform the general biology of diabetes 
 
All of the five hyperglycemia biomarkers studied herein (fasting glucose, HbA1c, 
fructosamine, glycated albumin and 1,5-AG) are correlated, but vary in the strength of 
their correlations.25,28  Similarly, the genetic variants associated with the biomarkers do 
not overlap as much as might be expected given that each is meant to reflect glycemic 
status. This may be because some of the genetic variants are associated with the 
nonglycemic aspects of the biomarkers (e.g., erythrocytes in HbA1c), or because the 
different biomarkers reflect different biologic aspects of type 2 diabetes (e.g., fasting 
glucose as a measure of hepatic glucose output, 1,5-AG as a measure of glycemic 
excursions, and HbA1c, fructosamine and glycated albumin as measures of average 
glucose levels over time). Conversely, variants that are associated with all of the 
glycemia biomarkers are likely to be more specific to type 2 diabetes. We used the 
similarities and differences in biomarker genetics to inform biomarker and diabetes 
biology. 
 
This dissertation was undertaken to address the following research questions: 
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How much of fructosamine, glycated albumin and 1,5-AG is under genetic control, 
and how does this compare to HbA1c and fasting glucose? 
 
Aim 1: Determine the narrow-sense and SNP-based heritability of biomarkers of type 2 
diabetes (fructosamine, glycated albumin, 1,5-AG, fasting glucose, HbA1c) using 
genome-wide association (GWAS) data from a single large-population based cohort.  
Hypothesis 1: There is a genetic component to nontraditional glycemic markers, 
which can be quantified and will inform the amount of variation due to genetics 
for each marker.  Comparing narrow-sense and SNP-based heritabilities will 
inform the genetic architecture of these biomarkers. 
 
What specific variants contribute to the genetic component of fructosamine and 
glycated albumin? Do these variants overlap with other glycemic biomarkers, and 
are the variants “glycemic” (diabetes related) or “nonglycemic” (limitation of the 
test)? 
 
Aim 2: Identify common genetic variants, both independent and shared with other 
glycemic biomarkers, associated with fructosamine and glycated albumin across the 
genome. 
 Hypothesis 2: Common variants are associated with fructosamine and glycated 
albumin, which may be glycemic or nonglycemic. 
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Aim 3: Identify rare, exonic variants associated with fructosamine and glycated albumin 
using a univariate approach, and identify additional common and rare variants using 
multivariate phenotype analyses. 
 Hypothesis 3: Rare variants are associated with fructosamine and glycated 
albumin.  In addition, the increased power of multivariate phenotype analysis over 
single phenotype analysis will identify additional variants associated with 
fructosamine and glycated albumin which were not identified in the single 
phenotype analysis. 
 
What specific variants contribute to the genetic component of 1,5-AG? Do these 
variants overlap with variants associated with other glycemic biomarkers, and are 
the variants “glycemic” (diabetes related) or “nonglycemic” (limitation of the test)? 
 
Aim 4: Identify rare, exonic genetic variants associated with 1,5-AG that may contribute 
to its overall genetic architecture. 
Hypothesis 4: There are rare variants that underlie the genetic architecture of 1,5-
AG. These rare variants may reflect glycemic and nonglycemic genetic control of 
nontraditional glycemic markers. 
 
Discerning the genetics of fructosamine, glycated albumin and 1,5-AG sought to 
inform these markers’ ability to accurately reflect blood glucose levels, with potential 
implications for their use in the setting of diabetes care and inform diabetes-related 
mechanisms not captured by other measures. 
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1.8 Tables and Figures 
 




Figure 1.2. Genes with known genetic variants associated with hyperglycemia 
biomarkers.  Blue indicates “glycemic” genes and orange indicates “erythrocytic” genes 







Figure 1.3. Manhattan plot for GWAS of 1,5-anhydroglucitol in European American 





Figure 1.4. Glucose metabolism as a common and biologically plausible theme 
among the genes mapping into the identified loci. This figure shows their role in 
intestinal carbohydrate digestion as well as glucose and 1,5-AG reabsorption in gut and 
kidney.43
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Introduction: Nontraditional glycemic biomarkers including fructosamine, glycated 
albumin and 1,5-anhydroglucitol (1,5-AG) are potential alternatives or compliments to 
traditional measures of hyperglycemia.  Genetic variants are associated with these 
biomarkers, but the heritability, or extent to which genetics control their variation, is not 
known. 
Methods: Narrow-sense, SNP-based and bivariate heritabilities were estimated for 
traditional glycemic biomarkers (fasting glucose, HbA1c), and nontraditional biomarkers 
(fructosamine, glycated albumin, 1,5-AG) among white participants in the 
Atherosclerosis Risk in Communities (ARIC) Study (N=400 first-degree relatives, 
N=5,575 unrelated individuals). 
Results: Narrow-sense heritabilities (representing heritability from the entire genome) 
for nontraditional biomarkers were substantial (0.44 - 0.55) and comparable to HbA1c 
(0.34); the fasting glucose estimate was nonsignificant.  SNP-based heritabilities 
(representing heritability from common variants) were lower than narrow-sense 
heritabilities for all biomarkers. Bivariate heritabilities showed shared genetics between 
fructosamine and glycated albumin (0.46 narrow-sense, 1.00 SNP-based) and glycated 
albumin and 1,5-AG (0.50 narrow-sense, 0.47 SNP-based). 
Conclusions: Genetic factors contribute to a considerable proportion of the variance of 
fructosamine, glycated albumin and 1,5-AG and a portion of this heritability likely comes 




Type 2 diabetes is a major public health problem that affects over 10% of the US 
adult population and is associated with substantially increased risks of mortality and 
serious clinical outcomes such as heart disease, stroke, chronic kidney disease and 
retinopathy.1,2  Diabetes is defined by hyperglycemia, or elevated glucose concentrations 
in the blood.  Fasting glucose and hemoglobin A1c (HbA1c) are the most common 
biomarkers used for screening and diagnosis of diabetes, but have limitations. Fasting 
glucose requires substantial patient preparation (i.e., an eight-hour fast), has high pre-
analytic variability, is acutely affected by factors such as recent physical activity or 
illness, and has moderate intra-individual variability. HbA1c is less affected by these 
factors, but the interpretation of HbA1c can be problematic in the setting of altered red 
blood cell turnover or changes in hemoglobin, factors due to characteristics of the 
biomarker and unrelated to circulating glucose.2-5 The limitations of traditional measures 
of hyperglycemia have led to a growing interest in nontraditional biomarkers including 
fructosamine, glycated albumin and 1,5-anhydroglucitol (1,5-AG).3,6  
Fructosamine, glycated albumin and 1,5-AG are indirect measures of blood 
glucose levels. Fructosamine and glycated albumin are both biomarkers where glucose is 
bound to protein. Fructosamine is glucose bound to serum total protein, and glycated 
albumin is glucose bound to serum albumin. The majority of serum protein is comprised 
of albumin, thus there are expected similarities between these two biomarkers and they 
represent the average blood glucose over the previous ~2-3 weeks.7   
1,5-AG is a molecule structurally similar to glucose and is consumed through 
food.  During hyperglycemic conditions, when glucose exceeds the renal threshold, 
glucose is preferentially reabsorbed from urine by the kidney, leading to excretion of 1,5-
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AG in the urine and a reduction of serum 1,5-AG levels.  Blood 1,5-AG concentrations 
represent glycemic excursions above the renal threshold over the previous 1-2 weeks.8-10 
Heritability, the proportion of variance in a phenotype that can be attributed to 
genetics, is population specific, and is affected by the relative genetic and environmental 
impacts on the phenotype. Previous studies in various populations have estimated the 
narrow-sense heritability of fasting glucose to range from 0.30 to 0.70, and HbA1c to 
range from 0.20 to 0.75.11-19 Recent studies evaluating hundreds of metabolites using 
non-targeted assays have estimated the heritability of 1,5-AG to be 0.61 to 0.6311,20 in 
population-based studies. To date, no study has estimated the heritability of fructosamine 
or glycated albumin. Quantifying the genetic contribution of these biomarkers will inform 
the extent to which genetics may play a role in these non-traditional biomarkers, and 
determine if they are comparable to traditional diabetes biomarker (fasting glucose and 
HbA1c) heritabilities.  
An underlying assumption of heritability is that if a trait is heritable, individuals 
who are more closely related will have more similar phenotypes than those who share 
less genetics (i.e., are distantly related or unrelated).  Traditional heritability methods use 
closely related individuals (first- and second-degree relatives) and infer the degree of 
shared genetics based on family structure.  These methods provide estimates of narrow-
sense heritability (ℎ2), or the proportion of variance in a phenotype passed down from 
parents to offspring.  In newer SNP-based (ℎ𝑆𝑆𝑆𝑆𝑆𝑆2 ) heritability methods, the amount of 
shared genetics among unrelated individuals can be estimated using measured genotypes, 
because all members of a species have a common ancestor, they share a small amount of 
their genomes.21,22  Genotyped variants are often available from genome-wide microarray 
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platforms used in genome-wide association studies (GWAS), which target common or 
less frequent SNPs with minor allele frequency (MAF)>0.01, and thus ℎ𝑆𝑆𝑆𝑆𝑆𝑆2  generally 
represents the genetic contribution of these more common variants.  Comparing ℎ𝑆𝑆𝑆𝑆𝑆𝑆2  and 
ℎ2 (representing the entire proportion of a phenotype due to genetics) can inform the 
genetic architecture of a trait, representing the proportion due to common variants.  
In this analysis, both narrow-sense and SNP-based heritability were estimated for 
fructosamine, glycated albumin and 1,5-AG using the same participants from the 





 The ARIC Study is a prospective cohort study initiated in 1987 to evaluate risk 
factors for cardiovascular disease in a community-based setting. Briefly, participants 
were recruited from four study sites: Forsyth, North Carolina; suburban Minneapolis, 
Minnesota; Jackson, Mississippi; and Washington County, Maryland.  Overall, 15,792 
middle-aged adults participated in the initial study visit (visit 1, 1987-1989), with 6 
subsequent study visits (1990-2017). All study participants provided written informed 
consent, and the study protocols were approved by the relevant institutional review 
boards.23 
Glycemic biomarkers 
Samples for all glycemic biomarkers were collected at ARIC visit 2 (1990-1992). 
Fructosamine (Roche Diagnostics, Indianapolis IN, USA), glycated albumin (GA-L 
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Asashi Kasei Pharma Corporation, Tokyo, Japan) and 1,5-AG (GlycoMark, Winston-
Salem, NC) were measured in 2012-2013 using a Roche Modular P800 system from 
samples stored at -70°C. Glucose was measured at visit 2 using the Roche Hitachi 911 
analyzer using the hexokinase method (Roche Diagnostics). HbA1c was measured at visit 
2 in stored whole blood samples using high performance liquid chromatography, using 
NGSP-certified assays standardized to the Diabetes Control and Complications Trial.24  
Genotyping and Quality Control 
Genotyping was performed using the Affymetrix 6.0 array. Samples with sex 
mismatches, genetic outliers, failed concordance with Taqman genotypes, or missingness 
>98% were excluded.  First-degree relatives were defined by a DST value>0.8 (DST = 
IBS distance (IBS2 + 0.5*IBS1) / (N SNP pairs)) generated from PLINK.25  Both 
members of each first-degree relative pair were included in the narrow-sense heritability 
estimation, and one member of a first-degree relative pair were excluded in SNP-based 
heritability estimation.  SNPs were excluded if missingness was >5%, Hardy-Weinberg 
Equilibrium (HWE)<0.00001, or low minor allele frequency (MAF) <0.005.  Imputation 
was pre-phased using ShapeIt (v1.r532) and then imputed using IMPUTE2 to 1,000 
Genomes Phase I (March 2012).26  
From the 30,038,522 imputed SNPs, SNPs were excluded if they had bases other 
than G, C, T or A, had duplicate base pair positions, imputation quality info score<0.99 
and minor allele frequency (MAF)<0.01 to obtain a dataset with 3,224,517 SNPs.  
Imputed scores were converted to hard calls for the SNP-based heritability analyses using 
PLINK.25 
Family-based study sample for narrow-sense heritability 
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Through genotyping, 384 first-degree relative pairs were identified (688 
individuals, some were part of multiple pairs). Individuals were excluded if they met the 
following criteria: failed genetic quality control (N=50), did not attend visit 2 (N=29), did 
not fast for at least 8 hours (N=11) or missing fasting status (N=1), had diagnosed 
diabetes (N=32), or missing fasting glucose, HbA1c, fructosamine, glycated albumin, and 
1,5-AG data (N=40).  Individuals were further excluded if their related pair member did 
not pass quality control (N=91), potential parent-child relationships (N=20, as pedigree 
data was not available, types of first degree relatives could not be distinguished based on 
genetics alone and thus pairs with >15 year age difference were excluded), and likely 
monozygotic twins (first-degree relatives with the same age and sex, N=14), leaving 400 
individuals who were members of sibling-pairs (Supplemental Figure 2.1). 
Narrow-sense heritability analysis 
Narrow-sense heritability was estimated using the variance components method 
using the program SOLAR-Eclipse.27 This method uses a linear mixed model, with 
covariates (age, sex and ARIC study center) as fixed effects and genetics and 
environment as random effects.  It partitions the variance between genetic and 
environmental effects and then heritability is calculated as the ratio of genetic variance to 
the total variance.  The distributions of all glycemic biomarkers were skewed to the right 
among all participants (Supplemental Figure 2.2), and were therefore inverse normal 
transformed for all analyses.   
 
SNP-based heritability study sample 
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  The present study was restricted to self-identified white individuals because of 
limited power due to the smaller sample size of self-identified black participants 
(N=1,483 after exclusions; recommended sample size for ℎ𝑆𝑆𝑆𝑆𝑆𝑆2 =4,00024). Of the 9,044 
white ARIC participants with available genotyping data, participants with low quality 
genotype data (missingness>2%; N=290), did not attend ARIC visit 2 (N=313), did not 
fast for at least 8 hours (N=147) or missing fasting status (N=11), individuals with 
diagnosed diabetes (self-reported physician diagnosis or use of diabetes medications; 
N=480), or missing fasting glucose, HbA1c, fructosamine, glycated albumin, and 1,5-AG 
data (N=587), were excluded (Supplemental Figure 2.1). 
LDAK SNP-based heritability analysis 
The method Linkage Disequilibrium Adjusted Kinships (LDAK) was used to 
analyze SNP-based heritability for fasting glucose, HbA1c, fructosamine, glycated 
albumin and 1,5-AG.21,28 This method employs a linear mixed model, with covariates 
such as age and sex as fixed effects and a genetic relationship matrix (GRM) calculated 
from genotyped SNPs for all pairs of individuals as random effects. The variance of the 
random effects is partitioned to isolate the variance due to genetics, and restriction 
maximum likelihood estimation is then used to estimate that variance. Heritability is then 
calculated as the proportion of total variance in the outcome due to genetics.  The first 
step in LDAK is to calculate weights for each SNP, dividing the genome into 
approximately 1000kb sections and weighting SNPs based on the local LD structure such 
that areas of high LD had lower weights than those with low LD.  The total weight of 
these SNPs was 113,120, representing the approximate number of independent loci 
evaluated. 
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Closely related individuals may affect SNP heritability analysis due to their 
shared environment or shared regions of LD, and hence we excluded them from analysis.  
To determine relatedness, kinship was calculated based on a thinned set of SNPs (not 
within 1Mb of each other or in LD, with r2>0.2) using alpha = -0.25 (alpha is a parameter 
representing the relationship between heritability and MAF). Individuals were excluded 
so that no pair of individuals had a kinship value greater than the smallest observed 
kinship (-0.025, approximately no more related than cousins twice or thrice removed). 
Our analytic sample contained 5,575 individuals (Supplemental Figure 2.1).  The ARIC 
study included a large percentage of married participants29 (N=4,500 spousal pairs, 57% 
of individuals who attended visit 1), which represents a form of shared environment.  
However, the biomarker correlations among married couples was low (<0.10). 
In each analysis, age, sex, ARIC study center, and the top 20 principal 
components (PC) were included as covariates. Predictor loadings from 1000 genomes 
were projected onto our data and the top 10 loadings were controlled for as recommended 
by the LDAK developers.28 For each biomarker, strongly associated SNPs were evaluated 
using linear regression and inflation due to population substructure by calculating 
heritability separately in four chunks of chromosomes (chromosomes 1-3, 4-7, 8-11, 12-
22) and comparing the sum of the heritabilities from the chunks to the heritability 
calculated using all of the chromosomes. If population substructure was present, the 
chromosomes would be correlated and hence the sum of heritability from the four chunks 
would be greater than heritability from all of the chromosomes (because each chunk 
would be representing more than just the heritability from the chromosomes in that 
chunk). Sensitivity analyses were performed excluding undiagnosed diabetes cases 
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(defined as fasting for at least 8 hours and glucose ≥126 mg/dL) from the heritability 
estimations. 
GCTA SNP-based heritability analysis 
Because there has been much debate but no consensus in the literature as to 
whether LDAK or the originally proposed SNP-based heritability method, Genome-wide 
Complex Trait Analysis (GCTA)22 provide more accurate SNP-based heritability 
estimates, 28,30-32 both methods were used in this analysis.  Due to sample size constraints, 
the most recent version of GCTA (GCTA-LDMS) did not run and therefore the original 
version of GCTA (GCTA-SC) was used. Individuals with kinship>0.05 were removed, 
leaving 6,443 individuals.  A genetic relationship matrix was calculated and SNP-based 
heritabilities were estimated controlling for age, sex, ARIC study center and the first 10 
principal components.  
Bivariate heritability analyses 
To explore the shared heritability among the glycemic biomarkers, bivariate 
heritability was performed, which calculates the percentage of heritability shared across 
two traits.  Bivariate heritability models two traits as the outcome and estimates the 
genetic correlation between the traits.  A negative correlation (between -1 and 0) 
indicates that the same genes increase the values of one trait while decreasing the values 
of the other trait, and a positive correlation (between 0 and 1) indicates that the same 
genes increase the values of both traits.  Narrow-sense bivariate heritability was 
estimated using SOLAR-Eclipse and SNP-based bivariate heritability using GCTA. 
 
2.4 Results  
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 There were 5,575 unrelated individuals in the SNP-based heritability analytic 
sample and 400 first-degree relatives in the narrow-sense heritability analytic sample. 
Approximately half of the participants were female. Mean biomarker values were similar 
across both samples, and 5-7% of samples had undiagnosed diabetes (Table 2.1). 
Narrow-sense heritability  
 The narrow-sense heritability estimates using sibling-pairs for 1,5-AG (ℎ2=0.55), 
glycated albumin (ℎ2=0.45) and fructosamine (ℎ2=0.44) were statistically significant 
(p<1.9x10-4) (Figure 2.1, Table 2.2) and comparable to HbA1c (ℎ2= 0.34). The fasting 
glucose estimate was not significant (p=0.43), but analysis using visit 1 data (N=522) 
estimated heritability was 0.23 (p=0.03). 
SNP-based heritability  
 The glycated albumin SNP-based heritability estimated using LDAK was (ℎ𝑆𝑆𝑆𝑆𝑆𝑆2  = 
0.30), followed by 1,5-AG (ℎ𝑆𝑆𝑆𝑆𝑆𝑆2  = 0.17) and fructosamine (ℎ𝑆𝑆𝑆𝑆𝑆𝑆2  = 0.13) (Figure 2.1, 
Table 2.2).  HbA1c had similar SNP-based heritability to the nontraditional biomarkers 
(ℎ𝑆𝑆𝑆𝑆𝑆𝑆2  = 0.30).  The fasting glucose result was nonsignificant (p=0.11).  Excluding 
undiagnosed diabetes cases (N=5,281) had little impact on these estimates (Table 2.2).  
Inflation for SNP-based heritability of the biomarkers was low (<3.3%).   
 SNP-based heritabilities estimated by GCTA were lower than estimates using 
LDAK. Fructosamine (ℎ𝑆𝑆𝑆𝑆𝑆𝑆2  = 0.11), glycated albumin (ℎ𝑆𝑆𝑆𝑆𝑆𝑆2  = 0.10), 1,5-AG (ℎ𝑆𝑆𝑆𝑆𝑆𝑆2  = 
0.15)  and HbA1c (ℎ𝑆𝑆𝑆𝑆𝑆𝑆2  = 0.17) (Figure 2.1, Table 2.2).  The fasting glucose estimate 
was not significant (p=0.08). 
Bivariate heritability analyses 
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 Bivariate heritability estimates for fructosamine and glycated albumin showed 
shared genetics using SOLAR-Eclipse (0.46) with nearly complete overlap using GCTA 
(0.99).  Glycated albumin and 1,5-AG had shared genetics which influence these traits in 
opposite directions, consistent with the inverse correlation of these biomarkers (-0.50 in 
SOLAR, -0.47 in GCTA); Supplemental Table 2.1).  No other pairs of biomarkers had 
significantly shared heritability using GCTA or SOLAR-Eclipse.  
 
2.5 Discussion 
 In this study, both narrow-sense and SNP-based heritabilities were estimated for 
nontraditional glycemic biomarkers. Because heritability is a population-specific measure 
that depends on relative genetic and environmental factors, it is important to estimate 
heritabilities in the same population in order to compare heritabilities across traits.  This 
was done this for both traditional and nontraditional glycemic biomarkers, using the same 
population of white individuals participating in the ARIC Study.   
Approximately half of the variation in fructosamine, glycated albumin and 1,5-
AG was estimated to be controlled by genetic factors.  Our results for 1,5-AG are 
consistent with previous estimations (0.55 in our study vs. 0.61 to 0.63 in previous 
studies).11,20  There are no published reports of the heritability of fructosamine and 
glycated albumin. Our results illustrate that genetics play an important role in 
nontraditional glycemic biomarkers, and may affect these markers in a similar manner to 
HbA1c.  Given that 60 variants are associated with HbA1c33 (heritability = 0.20 to 
0.75),12,13,15-18 it is likely that more than the currently discovered (1 for fructosamine, 1 
for glycated albumin, 7 for 1,5-AG)34,35 variants are associated with nontraditional 
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glycemic biomarkers and these low numbers of SNPs may reflect the limited sample 
sizes to date for GWAS and sequencing studies for these biomarkers.  The nonsignificant 
heritability estimates for fasting glucose may be in part due to its pre-analytic and intra-
individual variability.  Although nonsignificant, SNP-based heritability was similar to 
that estimated in a previous study in ARIC using participants from visit 1 (ℎ𝑆𝑆𝑆𝑆𝑆𝑆2  =0.13 vs 
0.8 in our LDAK analyses).36  The significant and larger narrow-sense heritability 
estimated using visit 1 data (N=521, ℎ2=0.23, p=0.03) indicates that the smaller sample 
from visit 2 likely reduced power to estimate fasting glucose heritability. 
As expected, the SNP-based heritabilities were lower than the narrow-sense 
heritabilities. SNP-based methods estimate heritability based on the variants for which 
data is collected (genotyped or sequenced), while narrow-sense heritability among related 
individuals is based on the entire genome.  Additionally, narrow-sense heritability may be 
influenced by shared environment among family members, which does not impact SNP-
heritability estimates. For all biomarkers, SNP-based heritabilities represented a portion 
of the narrow-sense heritability, indicating that the genetic influences on these traits is 
likely due to both common and rare variants.  
Bivariate heritability was also estimated across all of the biomarkers, examining 
how much heritability is shared between them.  The shared heritability between 
fructosamine and glycated albumin was significant, suggesting a substantial portion of 
overlapping genetics.  However, this was expected due to the biological similarity of 
these two measures (80% of glycated proteins (i.e., fructosamine) are glycated 
albumin).37,38  While the biomarkers in the present study all aim to capture 
hyperglycemia, some variability in these measures may be explained by non-glycemic 
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factors, which may be particularly important in the non-diabetic range.  Alternatively, it 
could simply indicate the biomarkers are under control of different genes for other 
reasons such as the different time frames each biomarker represents (2-3 weeks for 
fructosamine and glycated albumin, 1-2 weeks for 1,5-AG 2-3 months for HbA1c, 
instantaneous for fasting glucose) or the differences in variability of these measures.  
Unfortunately, the lack of significance across the other bivariate analyses limit our ability 
to draw other conclusions about the amount of shared genetics across the other 
biomarkers. 
The substantial heritability estimates for nontraditional biomarkers indicate a 
strong genetic component. Additional studies focused on the identification of genetic  
variants associated with fructosamine, glycated albumin and 1,5-AG will inform the 







2.6 Tables and Figures 
 
Table 2.1. Demographic and clinical characteristics in unrelated and first-degree relative 
study participants1  
SNP-based heritability  Narrow-sense heritability  




Female  54% 55% 
Age 57 (5.7) 58 (5.3) 
Fructosamine (µmol/L)  227 (23) 227 (22) 
Glycated albumin (%) 12.6 (1.6) 12.5 (1.5) 
1,5-AG (µg/mL)  18.7 (5.7) 19.9 (6.4) 
HbA1c (%) 5.4 (0.5) 5.5 (0.6) 
Fasting glucose (mg/dL) 104 (17) 104 (16) 
Undiagnosed diabetes2 5% 7% 
1Continuous variables shown as mean (SD) and categorical variables shown as % 
2Undiagnosed diabetes defined as fasting and glucose≥126 or nonfasting and 
glucose≥200
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Table 2.2. SNP-based (ℎ𝑆𝑆𝑆𝑆𝑆𝑆2 )and narrow-sense (ℎ2) heritability estimates for glycemic biomarkers1 
 ℎ2 (SOLAR) ℎ𝑆𝑆𝑆𝑆𝑆𝑆2  (LDAK2) ℎ𝑆𝑆𝑆𝑆𝑆𝑆2  (LDAK2)  
no undiagnosed diabetes 
ℎ𝑆𝑆𝑆𝑆𝑆𝑆2  (GCTA) 
 Heritability P-value Heritability (SD) P-value Heritability (SD) P-value Heritability (SE) P-value 
Fructosamine 0.44 2.9E-04 0.13 (0.06) 0.01 0.14 (0.07) 0.01 0.11 (0.05) 7.1E-03 
Glycated albumin 0.45 1.8E-04 0.30 (0.07) 8.6E-07 0.27 (0.07) 1.7E-05 0.13 (0.04) 1.1E-03 
1,5-AG 0.55 1.3E-05 0.17 (0.06) 3.6E-03 0.20 (0.07) 3.0E-03 0.11 (0.05) 7.2E-03 
HbA1c 0.34 0.01 0.30 (0.07) 2.6E-06 0.37 (0.07) 1.1E-07 0.20 (0.05) 4.3E-06 
Fasting glucose 2 0.43 8 (7) 0.11 13 (7) 0.03 5 (4) 0.13 
1LDAK N=5575, relatedness cutoff=0.25; GCTA N=6443, relatedness cutoff=0.05; SOLAR N=400 
2LDAK inflation <3.3% for all heritability estimates 
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Figure 2.1. Heritability estimates for glycemic biomarkers by method 
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Heritability Estimates for Glycemic Biomarkers




Supplemental Table 2.1. Bivariate heritability results 
 Fructosamine Glycated Albumin 1,5-AG HbA1c 
 




Glycated Albumin 100 (12)*  -50* (p=0.009) 3 (p=0.89) 
1,5-AG -31 (21) -47 (21)*  -30 (p=0.18) 
HbA1c 24 (19) 15 (20) 13 (18)  
 GCTA heritability (SE)  
*p<0.05  
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3.1 Abstract  
 
Fructosamine and glycated albumin are potentially useful alternatives to hemoglobin A1c 
(HbA1c) as diabetes biomarkers. The genetic determinants of fructosamine and glycated 
albumin, however, are unknown. We performed genome-wide association studies of 
fructosamine and glycated albumin among 2,104 black and 7,647 white participants 
without diabetes in the Atherosclerosis Risk in Communities (ARIC) Study and 
replicated findings in the Coronary Artery Risk Development in Young Adults 
(CARDIA) study. Among whites, rs34459162, a novel missense SNP in RCN3, was 
associated with fructosamine (p=5.3x10-9), and rs1260236, a known diabetes-related 
missense mutation in GCKR, was associated with percent glycated albumin (p=5.9x10-9) 
and replicated in CARDIA. We also found two novel associations among blacks: an 
intergenic SNP, rs2438321, associated with fructosamine (p=6.2x10-9), and an intronic 
variant in PRKCA, rs59443763, associated with percent glycated albumin (p=4.1x10-9), 
but these results did not replicate. Few established fasting glucose or HbA1c SNPs were 
also associated with fructosamine or glycated albumin. Overall, we found genetic 
variants associated with the glycemic information captured by fructosamine and glycated 
albumin, as well as with their non-glycemic component. This highlights the importance 
of examining the genetics of hyperglycemia biomarkers to understand the information 






Diabetes is defined by elevated blood glucose levels (hyperglycemia). 
Hemoglobin A1c (HbA1c) is formed as glucose binds to hemoglobin molecules within 
erythrocytes and is the standard clinical measure of chronic hyperglycemia used to 
diagnose and monitor diabetes(1). However, factors related to the nonglycemic portion of 
HbA1c such as erythrocyte turnover and hemoglobin characteristics can affect HbA1c 
values(2). 
There is growing interest in fructosamine and glycated albumin, additional 
biomarkers of hyperglycemia that demonstrate associations with diabetes risk and 
complications similar to HbA1c(3-14). Fructosamine measures total serum protein bound 
to glucose. Glycated albumin is expressed as a percentage of serum albumin, the most 
abundant serum protein. Both biomarkers reflect glucose exposure over a shorter period 
of time (2-4 weeks) than HbA1c (2-3 months)(15). Fructosamine may be used to monitor 
glycemic control in clinical situations where HbA1c is problematic such as in the setting 
of anemia or hemoglobinopathies(16). While glycated albumin is not frequently used in 
the U.S., it is widely used in Japan and other countries as a complement to HbA1c to 
monitor short-term glycemic control(17). 
The genetics of HbA1c and glucose have been well studied, however genetic 
factors that influence fructosamine and glycated albumin are uncharacterized. Of the 
known genome-wide association study (GWAS) variants associated with fasting glucose 
and HbA1c in European ancestry cohorts, few loci are associated with both(18). Many 
HbA1c variants are in genes related to hematologic factors rather than glucose 
metabolism,(19-21) while fasting glucose variants are in genes involved in glucose 
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metabolism (although these variants are not all associated with diabetes)(22-24). This 
lack of overlap suggests that some underlying genetic variants are specific to particular 
biomarkers of hyperglycemia rather than to type 2 diabetes. Understanding the genetic 
determinants of fructosamine and glycated albumin should help in the interpretation of 
these tests, and possibly extend our understanding of the pathophysiology of glucose 
metabolism. In particular, comparing the genetic overlap between different measures of 
glycemia may provide insight into the contributions of glycemic vs. nonglycemic gene 
variants, i.e. to what extent genetic factors operate via pathways directly relevant to 
diabetes pathophysiology (“glycemic”) or operate via glycemic-independent pathways 
that do not influence glucose metabolism or diabetes risk (“nonglycemic”, such as the 
hematologic variants associated with HbA1c). If nonglycemic genetic variants strongly 
impact fructosamine and glycated albumin, this may need to be taken into account in the 
interpretation of these biomarkers as measures of hyperglycemia. 
We conducted GWAS of fructosamine and glycated albumin in blacks and whites 
in the Atherosclerosis Risk in Communities (ARIC) Study. We also compared previously 
identified genetic determinants for HbA1c and fasting glucose with fructosamine and 
glycated albumin to identify common genetic factors related to glucose metabolism and 




The Atherosclerosis Risk in Communities (ARIC) Study is an ongoing, 
prospective cohort of 15,792 participants initiated in 1987 (25). Participants were middle-
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aged adults recruited from four U.S. communities (Jackson, Mississippi; Forsyth County, 
North Carolina; Washington County, Maryland; and suburban Minneapolis, Minnesota). 
All study participants provided written informed consent and study protocols were 
approved by the relevant institutional review boards. 
In the present study, we included 9,751 participants (7,647 whites and 2,104 
blacks) who attended visit 2 (1990-1992), consented for use of DNA, did not have 
diagnosed diabetes (self-reported diagnosis or use of diabetes medications), had valid 
data on fructosamine and glycated albumin, and had genotyping data meeting quality 
control criteria (Supplemental Figure 1).  Individuals with diagnosed diabetes were 
excluded to avoid potential bias caused by altered glucose levels as a result of diabetes 
treatment. 
Genotyping 
ARIC participants were genotyped using the Affymetrix 6.0 array and imputed 
separately by race using IMPUTE2(26) with the 1000 Genomes Project Phase I (March 
2012) reference panel. Quality control excluded individuals based on SNP missing 
rate>5%, sex mismatch, high discordance with previous Taqman assay genotypes, 
genetic outlier status, and relatedness. SNPs with IMPUTE info score<0.8 or minor allele 
frequency (MAF)<0.05 were excluded. Only autosomal variants (on chromosomes 1-22) 
were considered.  Principal components analysis was used to estimate population 
substructure with EIGENSTRAT(27).  
Glycemic Markers 
Fructosamine (Roche Diagnostics, Indianapolis IN, USA), glycated albumin and 
serum albumin (GA-L Asashi Kasei Pharma Corporation, Tokyo, Japan) were measured 
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in 2012-2013 using a Roche Modular P800 system from serum collected at visit 2 and 
stored at -70oC(3). Percent glycated albumin was calculated per the manufacturer’s 
protocol: [(glycated albumin concentration in g/dL / serum albumin concentration in 
g/dL)*100/1.14] + 2.9. We also examined total glycated albumin (g/dL) as well as serum 
albumin (g/dL) to help distinguish genetic factors specific to serum protein concentration 
vs hyperglycemia.  
Serum glucose was measured on the Roche Hitachi 911 analyzer using the 
hexokinase method (Roche Diagnostics), and HbA1c was measured from whole blood 
stored at -70oC using high performance liquid chromatography, standardized to the assay 
used in the Diabetes Control and Complications Trial(28).  
Statistical Analysis 
GWAS in blacks and whites were conducted using SNPTEST v2(29) for all 
glycemic biomarkers using imputed allele dosage and controlling for age, sex, field 
center, and the first 10 principal components under an additive genetic model. 
Fructosamine and glycated albumin (both percent (%) and total (g/dL)) were transformed 
on the natural log scale; therefore, the effect sizes are the change in the natural log of the 
biomarker per each additional risk allele.  Exponentiating the effect sizes thus 
corresponds to the percent higher or lower biomarker levels per additional risk allele. 
Fasting glucose and HbA1c were not transformed. To identify additional independent 
SNPs associated with the traits, we performed conditional analyses for genome-wide 
significant finding. Using fructosamine, percent glycated albumin, and total glycated 
albumin as the dependent variable and the index SNP (SNP with the lowest p-value in a 
region showing a genome-wide significant association) as a covariate, we evaluated the 
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association between other SNPs with a minor allele frequency (MAF) ≥1% within 250 
kB of the index SNP or between recombination hotspots surrounding the index SNP. To 
estimate percentage of variance explained by each SNP, we used the equation: Ri2 = bi2 * 
var(SNPi)/var(y) where bi = the effect size of the association between the SNPi and the 
phenotype y, var(SNPi) is 2 * MAFSNPi x (1-MAFSNPi) and var(y) is the variance in the 
phenotype(30,31). We meta-analyzed across ancestries using a random-effects model by 
GWAMA(32). 
In sensitivity analyses, we performed GWAS excluding undiagnosed diabetes 
cases (participants with fasting glucose ≥126 mg/dL or non-fasting glucose>200 mg/dl). 
To further evaluate the genetic variants pertaining to serum protein levels rather than 
hyperglycemia, we evaluated the top fructosamine and glycated albumin SNPs for 
association with total glycated albumin and with serum albumin (transformed on the 
natural log scale). To determine the extent to which glycemic biomarkers shared genetics, 
we calculated genetic correlations between the biomarkers using ARIC summary 
statistics with the LDSC program, using the precomputed LD scores from 1000 genomes 
European data(33). 
Replication 
Significant associations between genetic variants and fructosamine and percent 
glycated albumin in ARIC were evaluated for replication in the Coronary Artery Risk 
Development in Young Adults (CARDIA) cohort, a prospective cohort study initiated in 
1985 to evaluate risk factors for heart disease among unrelated young adults(34).   
Serum specimens from 2005-2006 were stored at –70°C and used to analyze 
glycated albumin and fructosamine in 2014 using a Roche COBAS 6000 chemistry 
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analyzer (Roche Diagnostics Corporation, Indianapolis, Indiana, USA). Glycated albumin 
and fructosamine were measured using the same assays used in ARIC (Lucica GA-L, 
Asahi Kasei Pharma Corporation, Tokyo, Japan; Roche Diagnostics, Indianapolis IN, 
USA; respectively).  
Genotyping was performed using the Affymetrix 6.0 array.  Standard quality 
control metrics were applied, and imputation to HapMap Phase II, Build 36, Release 22 
was done using MACH(35). Genetic, covariate, fructosamine and glycated albumin data 
were available on 1,304 whites and 608 blacks.  Individuals with diabetes (current use of 
glucose-lowering medications or fasting glucose ≥126 mg/dl were excluded from 
analysis. Linear regression analyses stratified by race were done for the association 
between significant ARIC SNPs and natural log transformed fructosamine and percent 
glycated albumin adjusted for age, sex, field center and the first three principal 
components.   
Statistical analysis was done using SAS (v9.4, SAS Institute, Cary, NC) (data 
manipulation) and ProbABELv0.2(36).  If the ARIC SNP was not available in the 
CARDIA dataset, we determined if proxy SNPs in linkage disequilibrium (LD) with the 
ARIC SNP (r2 > 0.7 from 1000 genomes phase 3v5 European population, GRCh37 
assembly using Single Nucleotide Polymorphisms Annotator (SNiPA)(37)) were 
available and if so, analyzed the associations with the proxy SNP. We considered a 
Bonferroni corrected one-sided p-value threshold of <0.05 (0.1/2 SNPs per race) for 
replication significance.  We meta-analyzed ARIC and CARDIA results using fixed-
effects inverse variance weighted model by METAL(38).  
Candidate SNP analysis 
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We additionally evaluated previously-identified fasting glucose (n=41) and 
HbA1c (n=46) candidate SNPs from the NHGRI-EBI Catalog of published GWAS using 
the search terms “fasting glucose” and “HbA1c” (http://www.ebi.ac.uk/gwas/ as of 
12/14/17) for association with fructosamine and percent glycated albumin in ARIC. SNPs 
were included if they were discovered in European ancestry cohorts, were genome-wide 
significant (p<5x10-8) and were not in linkage disequilibrium (LD) with each other (r2 < 
0.2, using SNiPA)(37). For the candidate SNP analyses, we used a study-wide 
significance threshold: two traits (fructosamine and glycated albumin), two races (black 
and white) and the number of candidate SNPs for each trait: p<4.6x10-4 (0.05/(2*2*27)) 
for fasting glucose and p<2.6x10-4 (0.05/(2*2*49)) for HbA1c.   
We additionally performed analyses controlling for these known fasting glucose 
and HbA1c SNPs compiled into scores.  Scores were calculated as the sum of the number 
of risk alleles, weighted by the effect size in ARIC among whites. 
Comparison of variance explained  
To compare the influence of glycemic and nonglycemic genetic variants on 
fructosamine and glycated albumin to that of HbA1c, we calculated the percent 
phenotypic variance explained by the SNPs in our study to those from published results 
of HbA1c.  In addition, we calculated variance explained by known fasting glucose and 
albumin SNPs (identified by the same criteria used for fasting glucose and HbA1c). 




Overall, 7,647 whites and 2,104 blacks from ARIC and 1,304 whites and 608 
blacks from CARDIA were included in this study (Supplemental Table 3.1).  Mean age 
in ARIC was higher (56-57 years), than in CARDIA (45-46 years). The cohorts had 
similar distribution of sex. CARDIA had a greater percentage of black participants and 
lower mean values for each measure of glycemia as compared to ARIC.   
We identified four genome-wide significant loci in ARIC, two associated with 
fructosamine and two with percent glycated albumin. Three of these variants, rs34459162 
intronic to RCN3, rs2438321 (intergenic), and rs59443763 intronic to PRKCA, have not 
previously been reported to be associated with any glycemic traits in humans (Table 3.1). 
None of the analyses showed evidence for inflation (Supplemental Figures 3.2-3.7). 
Among whites, rs34459162 (MAF=0.08), a missense SNP in RCN3 on 
chromosome 19, was significantly associated with 1.8% lower fructosamine per minor 
allele (p=5.3x10-9, variance explained=0.6%; Table 3.1, Figures 3.1-3.2). This SNP was 
also associated with total glycated albumin (p=3.8x10-8; Table 3.2). The association with 
percent glycated albumin approached genome-wide significance (p=7.3x10-8), but this 
SNP was not associated with fasting glucose or HbA1c (Table 3.2). A proxy for 
rs34459162, (rs8105626, in r2=1 rs34459162) was not associated in CARDIA for 
association with fructosamine (p=0.09) although the effect sizes were identical and meta-
analysis across the cohorts was significant (p=4.9x10-9, Table 3.1). Conditional analysis 
in ARIC showed that the additional 63 significant SNPs in the region became 
nonsignificant after conditioning on rs34459162. In blacks, rs34459162 did not meet the 
info score>0.8 threshold and thus was not analyzed (Table 3.2).   
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Among whites, rs1260326 (also known as rs343480), a known missense mutation 
in GCKR on chromosome 2 (MAF=0.41), was significantly associated with 1.1% lower 
levels of percent glycated albumin per minor allele (p=5.3x10-9, variance 
explained=0.3%; Supplemental Figure 3.8-3.9, Table 3.1). The association with percent 
glycated albumin was also significant in CARDIA (p=0.04), with similar percent 
difference (0.8% lower per minor allele) and genome-wide significant meta-analysis 
results (2.3x10-8, Table 3.1). The conditional analysis did not reveal additional 
independent signals in this region. This SNP was not associated with any biomarker 
among blacks (MAF=0.14, Table 3.2, Supplemental Table 3.2), but power was limited,  
and the meta-analysis across ancestries was not significant (Table 3.1, Supplemental 
Figure 3.10).  
Among blacks, rs2438321 on chromosome 11 (MAF=0.11) was associated with 
3.5% higher levels of fructosamine per minor allele at a genome-wide significant level 
(p=6.2x10-9, variance explained=1.8%; Table 3.1, Supplemental Figure 3.11-3.12), and 
approached significance with percent glycated albumin (p=6.4x10-5), and total glycated 
albumin (p=2.0x10-6) (Table 3.2). Rs2438321 was not associated with HbA1c in blacks 
and was not associated with any of the markers of hyperglycemia in whites independently 
or in a meta-analysis across ancestries (Table 3.1, Table 3.2). This SNP was not 
available in the CARDIA dataset, however a proxy SNP in perfect LD (r2=1, rs35256014, 
MAF=0.06) was present but did not replicate the association with fructosamine in blacks 
(p=0.57) and meta-analysis were also nonsignificant (Table 3.1, Supplemental Figure 
3.13). 
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An intronic variant, rs59443763, in PRKCA on chromosome 17 (MAF=0.06), was 
significantly associated with 5.4% higher percent glycated albumin per minor allele in 
blacks (p=4.9x10-9), variance explained=2%; Table 3.1, Supplemental Figure 3.14-
3.15). It was also associated with fructosamine (p=9.4x10-7) and total glycated albumin 
(p=5.8x10-7) although these associations did not meet genome-wide significance (Table 
3.2). This SNP was not significant among whites nor in trans-ancestry meta-analysis 
(Table 3.1, Table 3.2), but there was limited power to replicate (Supplemental Table 
3.2). No proxy SNPs with r2>0.7 were available in the CARDIA dataset and thus 
replication was not possible for this association.  
Sensitivity analyses 
In analyses which excluded participants with undiagnosed diabetes, genome-wide 
significant results remained for the white sample (N=7,229), but were no longer present 
among the reduced sample of black participants (N=1,878) (Supplemental Table 3.3).  
Of the SNPs significantly associated with fructosamine or glycated albumin, only 
rs2438321 in blacks (p=0.002) was significantly associated with serum albumin with a 
Bonferroni corrected p-value (0.05/(4 SNPs * 2 races) = 0.006) (Supplemental Table 
3.4).  
Controlling for fasting glucose or HbA1c variants did not reveal any additional 
genome-wide significant variants, but for glycated albumin controlling for HbA1c 
increased significance of rs34459162 (p=3.77x10-8) and controlling for fasting glucose 
score attenuated the p value for rs1260326 (p=0.0006) among whites. 
Fructosamine, percent glycated albumin and total glycated albumin had strong, 
statistically significant genetic correlations (0.92 to 1.17) indicating a large proportion of 
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shared genetics (Supplemental Table 3.5).  Correlations between fasting glucose and 
HbA1c with the other biomarkers were moderate to substantial but were not significant. 
Candidate SNP analysis 
We investigated SNPs previously identified in fasting glucose and HbA1c GWAS 
for association with fructosamine and percent glycated albumin. Nineteen of the 41 
fasting glucose SNPs were nominally (p<0.05) associated with fasting glucose, and 13 of 
these associations were in the same direction in blacks and whites (Table 3.3, 
Supplemental Table 3.6) and all but 8 were in the same direction as the discovery cohort 
in whites. Four variants (10%) were study-wide significantly associated with 
fructosamine and percent glycated albumin in whites, three of which were associated 
with percent glycated albumin and one of which was associated with fructosamine. No 
variants were study-wide significantly associated with fructosamine or percent glycated 
albumin in blacks.  
Thirty-one of 46 previously-identified HbA1c SNPs were nominally associated 
with HbA1c, 15 of which were associated in the same direction in blacks and whites 
(Table 3.4, Supplemental Table 3.7) and all but three in the same direction as the 
discovery cohort in whites.  Five SNPs (11%) demonstrated a study-wide significant 
association with fructosamine or glycated albumin in whites. All variants associated with 
multiple glycemic biomarkers had effects in the same direction. 
Percent Variance Explained 
SNPs associated with fasting glucose  (N=41, listed in Table 3) explained 1.4% of 
the variance in fructosamine, 3.2% of the variance in percent glycated albumin and 1.9% 
of the variance in total glycated albumin among whites.  Taking SNPs associated with 
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serum albumin from the GWAS catalogue explained 0.4% of the variance of 
fructosamine, 1.1% of the variance of percent glycated albumin and 0.7% of the variance 
of total glycated albumin among the white sample.  
 
3.5 Discussion  
We identified four SNPs significantly associated with fructosamine and glycated 
albumin among either whites or blacks, one which replicated in a second cohort, and 
three not previously associated with glycemic traits. Several known fasting glucose and 
HbA1c SNPs were significantly associated with fructosamine or glycated albumin. 
Among whites, rs1260326 was associated with percent glycated albumin. This 
variant reflects the same signal associated with type 2 diabetes and fasting glucose: it is 
in perfect LD with a known type 2 diabetes variant (r2=1 among 1000 genomes phase 3 
Europeans with rs145819220, from a recent large type 2 diabetes GWAS(39)) and in 
strong LD with a known fasting glucose variant (r2=0.91 with rs780094(38,39). 
Rs1260326 is located in glucokinase (hexokinase 4) regulator (GCKR), which encodes a 
regulatory protein primarily active in the liver that inhibits glucokinase (GCK), the 
enzyme in the first step of glycolysis and involved in converting glucose to glycogen for 
storage. GCK is considered a glucose sensor that helps maintain glucose homeostasis. 
The GCKR protein product inhibits the activity of GCK, increasing serum glucose levels. 
GCKR is an established type 2 diabetes gene(40-42), and is associated with multiple other 
traits including kidney disease, triglyceride levels and Crohn’s disease(43-45).  Thus, this 
variant likely represents part of a glycemic pathway, but it is interesting that in our study 
it is only significantly associated with one measure of hyperglycemia, approached 
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significance with fasting glucose (although controlling for fasting glucose score made 
this variant nonsignificant) and total glycated albumin, but is not associated with 
fructosamine or HbA1c, given the moderate to strong correlations and genetic 
correlations among the biomarkers  (Supplemental Table 3.8, 3.5). That GCKR is 
primarily expressed in the liver rather than the pancreas(46,47) aligns with the finding of 
association with fasting glucose, which measures hepatic glucose output. Albumin is also 
produced by the liver, while erythrocytes and hemoglobin are not likely affected by liver 
function, thus perhaps hepatic-specific genetic factors would be more likely to associate 
with percent glycated albumin levels than with HbA1c. It is also possible that HbA1c, 
affected by other glucose-altering factors, may mask the effect of rs1260326 on GCKR. 
Adjustment for serum albumin may explain the association with percent glycated 
albumin but not fructosamine. 
We also identified several variants of potential interest which were significant in 
ARIC but lacked replication. Among whites, rs34459162, in RCN3, was associated with 
fructosamine and total glycated albumin. RCN3 encodes reticulocalbin 3, an EF-hand 
calcium binding domain(48). This SNP was not associated with serum albumin in our 
analysis, but a SNP in perfect LD with rs34459162, rs2280401, was associated with total 
protein in a Japanese population(49) and serum albumin in an East Asian population(50), 
indicating a possible impact on fructosamine and glycated albumin through nonglycemic 
pathways. Among blacks, we found two novel variants: rs2438321 (intergenic and closest 
to CNTN5 which encodes a glycosylphosphatidylinositol (GPI)-anchored neuronal 
membrane protein, a member of the immunoglobulin superfamily and the contactin 
family.) associated with fructosamine and rs59443763 (PRKCA which encodes protein 
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kinase C alpha, ubiquitous in cellular processes) associated with percent glycated 
albumin at a genome-wide level of significance. There is no prior literature on either of 
these as potential glycemic loci in diabetes. While we had sufficient power to replicate 
the results for whites in CARDIA (Supplemental Table 3.2), we had low power among 
blacks, which may be why these SNPs did not replicate. These variants became 
nonsignificant after excluding undiagnosed diabetes, which may be due to the greater 
number of individuals with undiagnosed diabetes among blacks than whites.  Blacks had 
higher values of glycemic biomarkers, thus removing undiagnosed diabetes cases could 
have had a greater impact on associations among blacks than whites.  These variants 
should be evaluated in larger African ancestry datasets as they become available.  
Rs34459162, rs2438321 and rs59443763 are of potential interest, but as these SNPs 
currently lack replication, we cannot rule out false positive results.  
Results varied by ancestry for the SNPs available in both blacks and whites: 
neither SNP was significant in both blacks and whites, and meta-analyses were 
nonsignificant.  While this may partially be explained by differing allele frequencies 
(rs1260326: 0.41 in whites, 0.14 in blacks; rs2438321: 0.24 in whites, 0.11 in blacks), a 
differential effect by ancestry on fructosamine and glycated albumin is also possible. This 
may be particularly true for rs2438321, where the direction of effect differs across 
ancestries. 
In addition to investigating fructosamine and glycated albumin individually, 
comparing to traditional glycemic markers (fasting glucose and HbA1c) can help to 
clarify the biological pathways involved in diabetes. Fasting glucose-related SNPs 
explained almost twice the variance of percent glycated albumin than that of 
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fructosamine. This may reflect the adjustment for serum albumin with percent glycated 
albumin and not with fructosamine, allowing percent glycated albumin levels to be 
influenced more by glucose levels and less by albumin levels.  However, albumin SNPs 
also explained more variance of percent glycated albumin than that of fructosamine or 
total glycated albumin.  Given the small percentages, it is difficult to draw first 
conclusions from these results.  
Only five HbA1c variants were significantly associated with fructosamine or 
glycated albumin. This is consistent with the findings that the majority of HbA1c variants 
are related to erythrocyte and hemoglobin factors that we would not expect to be related 
to fructosamine or glycated albumin. Many associations of fructosamine or glycated 
albumin with HbA1c SNPs or fasting glucose SNPs were present in whites but not 
blacks. This is not surprising given the SNPs were originally detected in whites, and our 
sample size was larger for whites, with corresponding higher power to detect moderate 
associations. Not all of the previously discovered SNPs for fasting glucose and HbA1c 
replicated for those outcomes in our sample, but this again may have to do with lack of 
power. 
We found both glycemic and nonglycemic genetic factors influenced 
fructosamine and glycated albumin levels. We identified a likely glycemic variant in a 
gene associated with type 2 diabetes (GCKR) supporting its role in diabetes biology, and 
a likely nonglycemic variant in a gene (RCN3) that may reflect the biology of a 
biomarker (i.e., influencing amount of serum protein available to be glycated) rather than 
the biology of type 2 diabetes. This contribution of glycemic and nonglycemic variants is 
similar to the pattern of genetic contribution to HbA1c, for which the majority of genetic 
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variants are nonglycemic(19,20). In our study, previously identified nonglycemic 
variants(19-21) explained 3.4% of the variance in HbA1c, and the glycemic variants 
explained 2.1% (Supplemental Table 3.9). Despite the previous studies having much 
larger sample sizes (and thus more power to detect associations with HbA1c), the percent 
variance explained we found for fructosamine (0.6% by likely nonglycemic rs34459162) 
and glycated albumin (0.3% by likely glycemic rs1260326) was of a similar magnitude. 
Both Soranzo and Chen found that taking nonglycemic variants into account modestly 
impacted diabetes reclassification, and Wheeler found a more substantial effect(19-21). 
Given that that future, larger studies on fructosamine and glycated albumin will likely 
reveal other significant variants, it will be important to determine if the effect of 
nonglycemic variants is substantial enough to impact the clinical interpretation of 
fructosamine and glycated albumin.  
 A major limitation of this study was the limited sample size, particularly the 
smaller sample size in blacks. The differences in ancestries make replication of results 
difficult, particularly if allele frequencies differ, and warrant more studies focused on 
multi-ethnic populations. Also, the lack of an available SNP or proxy for rs59443763 in 
CARDIA, possibly due to the imputation reference panel (HapMap Phase II), impeded 
our ability to evaluate replication of this finding. In addition, the sample size for our 
replication cohort was much smaller than our discovery cohort, limiting our power to 
replicate the significant ARIC findings in blacks. 
 In summary, through GWAS in a community-based population of blacks and 
whites we identified and replicated two significant variants associated with fructosamine 
and/or glycated albumin, one of which was novel. These variants map into a likely 
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glycemic, known diabetes gene, and a likely nonglycemic gene. This highlights the utility 
of examining genetics of diabetes biomarkers both for providing insight into the 
pathophysiology of diabetes and for better understanding glucose–independent influences 




3.6 Tables and Figures 
 
 
Table 3.1. Genome-wide significant loci for fructosamine and percent glycated albumin.  


































rs34459162 RCN3 C/T Fructosamine 
(umol/L) 
W 0.08 -0.02 
(0.003) 
-2% 5.3E-9 0.6% 0.09 -0.02 
(0.014) 
-2% 0.09 -0.02 
(0.003) 
-2% 4.9E-9 - - - 
rs1260326 GCKR T/C Percent 
glycated 
albumin (%) 
W 0.41 -0.01 
(0.002) 
-1% 5.9E-9 0.3% 0.43 -0.01 
(0.004) 
-1% 0.04 -0.01 
(0.002) 





rs2438321 CNTN5 G/A Fructosamine 
(umol/L) 
B 0.11 0.03 
(0.006) 
3% 6.2E-9 1.8% 0.06 0.006 
(0.011) 
0.6% 0.57 0.03 
(0.005) 
3% 2.9E-8 0.02 
(0.02) 
2% 0.37 
rs59443763 PRKCA C/T Percent 
glycated 
albumin (%) 
B 0.06 0.05 
(0.009) 
5% 4.1E-9 2.0% - - - - - - - - - - 
 
*ARIC: N=7,647 whites, 2,104 blacks; CARDIA: N=1,304 whites, 608 blacks; ARIC+CARDIA is a meta-analysis across the cohorts, ARIC White+Black is a 
meta-analysis across the ancestries in ARIC 
†A1 is the minor allele in whites 
‡Mean change in ln(outcome) for each additional A1 allele 
§Percent higher or lower levels of the outcome for each additional copy of the minor allele, calculated as eß *100 
||rs34459162 and rs2438321 not available in CARDIA dataset, evaluated proxy SNPs rs8105626 and rs35256014, respectively in perfect LD (r2=1 with ARIC 
SNP).  
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Table 3.2. Genome-wide significant loci for fructosamine and percent glycated albumin and their association with total glycated 
albumin, fasting glucose and HbA1c in ARIC*,† 
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rs34459162 RCN3 C/T 









Black - - - - - - - - - - - - 
rs1260326 GCKR T/C 


















rs2438321 CNTN5 G/A 


















rs59443763 PRKCA C/T 
White 0.005 - - - - - - - - - - - 









*Genome-wide significant results are in bold 
†Fructosamine, glycated albumin percent and total glycated albumin are log transformed 
‡A1 is the minor allele in whites 




Table 3.3. Significance of associations between fasting glucose known genetic 
determinants and fructosamine and percent glycated albumin in ARIC*,† 
   White Blacks 

























rs10747083 P2RX2 G/A 0.33 0.95 0.76 0.14 0.16 0.17 0.11 0.95 
rs10830963 MTNR1B G/C 0.28 0.001 0.003 3.3E-07 0.07 0.13 0.03 0.38 
rs10885122 ADRA2A T/G 0.12 0.82 0.75 0.76 0.68 0.24 0.72 0.21 
rs11071657 C2CD4B G/A 0.38 0.50 0.81 0.52 0.12 0.98 0.95 0.43 
rs11558471 SLC30A8 G/A 0.32 0.005 8.2E-05 1.8E-05 0.09 0.31 0.18 0.65 
rs11603334 ARAP1 A/G 0.16 0.01 0.08 0.47 0.06 0.79 0.95 0.76 
rs11605924 CRY2 A/C 0.47 0.36 0.58 0.66 0.84 0.58 0.72 0.44 
rs11708067 ADCY5 G/A 0.23 0.07 0.001 0.01 0.16 0.002 0.003 0.03 
rs11715915 AMT T/C 0.30 0.30 0.74 0.04 0.23 0.06 0.37 0.31 
rs11920090 SLC2A2 A/T 0.13 0.004 0.002 0.34 0.35 0.47 0.30 0.28 
rs13179048 PCSK1 A/C 0.31 0.11 0.13 0.51 0.08 0.18 0.52 0.78 
rs1371614 DPYSL5 T/C 0.25 0.47 0.78 0.69 0.36 0.18 0.11 0.21 
rs143399767 YRNA C/A 0.01 0.65 0.24 0.55     
rs1483121 OR4S1 A/G 0.13 0.41 0.36 0.74 0.04 0.46 0.42 0.94 
rs16913693 IKBKAP G/T 0.03 0.60 0.78 0.11 0.25 0.73 0.68 0.91 
rs174550 FADS1 C/T 0.33 0.16 0.28 0.54 0.08 0.37 0.15 0.93 
rs17762454 RREB1 T/C 0.26 0.13 0.32 0.001 0.16 0.16 0.76 0.75 
rs2191349 TMEM195, DGKB G/T 0.46 0.17 0.36 0.02 0.44 0.58 0.73 0.004 
rs2293941 PDX1 A/G 0.22 0.02 0.005 0.03 0.17 0.38 0.60 0.77 
rs2302593 GIPR G/C 0.50 1.00 0.40 0.02 0.30 0.64 0.94 0.97 
rs2657879 GLS2 G/A 0.18 0.93 0.94 0.31 0.06 0.05 0.23 0.04 
rs2722425 ZMAT4 T/C 0.12 0.01 0.01 0.78 0.37 0.25 0.35 0.41 
rs340874 PROX1 T/C 0.45 0.42 0.82 0.40 0.17 0.36 0.74 0.15 
rs35767 IGF1 G/A 0.16 0.76 0.54 0.62 0.55 0.43 0.10 0.02 
rs3736594 MRPL33 C/A 0.26 0.11 0.07 0.25 0.43 0.07 0.03 0.62 
rs3783347 WARS T/G 0.22 0.45 0.51 0.57 0.06 0.44 0.60 0.94 
rs3829109 DNLZ A/G 0.29 0.003 0.13 0.16 0.18 0.51 0.39 0.46 
rs4506565 TCF7L2 T/A 0.31 3.9E-04 2.5E-05 2.7E-05 0.44 0.09 0.40 0.83 
rs4607517 GCK A/G 0.17 2.0E-04 0.003 5.0E-04 0.11 0.09 0.10 0.08 
rs4841132 PPP1R3B A/G 0.09 0.33 0.32 0.05 0.13 0.74 0.29 0.05 
rs560887 G6PC2 T/C 0.30 0.08 0.003 7.3E-05 0.05 0.81 0.58 0.91 
rs576674 KL G/A 0.16 0.45 0.50 0.33 0.61 0.17 0.26 0.11 
rs6048205 FOXA2 G/A 0.05 0.79 0.95 0.07 0.18 0.02 0.25 0.05 
rs6072275 TOP1 A/G 0.16 0.57 0.30 0.01 0.08 0.13 0.12 0.08 
rs6943153 GRB10 T/C 0.31 0.67 0.46 0.16 0.70 0.09 0.77 0.61 
rs7034200 GLIS3 A/C 0.49 0.19 0.04 0.03 0.61 0.18 0.02 0.11 
rs7651090 IGF2BP2 G/A 0.31 0.01 0.03 0.003 0.56 0.32 0.58 0.40 
rs7708285 ZBED3 G/A 0.30 0.32 0.64 0.71 0.15 0.56 0.52 0.16 
rs780094 GCKR T/C 0.40 0.05 5.7E-05 1.0E-04 0.18 0.75 0.96 0.90 
rs7944584 MADD T/A 0.27 0.56 0.76 0.05 0.04 0.98 0.38 0.77 
rs9368222 CDKAL1 A/C 0.27 0.19 0.09 0.27 0.20 0.96 0.80 0.68 
*Candidate SNPs selected from NHGRI database based on previous genome-wide significant associations 
†P-values that reach study-wide significance for fructosamine and glycated albumin, p<3.0x10-4 
(0.05/(2*2*41)) are in bold; P values that reach nominal significance (p<0.05) for fasting glucose in bold 
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Table 3.4. Significance of associations between HbA1c known genetic determinants and 
fructosamine and percent glycated albumin in ARIC*,† 
   Whites Blacks 























rs1046896 FN3KRP T/C 0.31 0.034 0.048 0.052 0.24 0.661 0.455 0.585 
rs10774625 ATXN2 G/A 0.48 0.571 0.032 0.008 0.09 0.221 0.142 0.503 
rs10823343 HK1 G/A 0.26 0.452 0.065 1.1E-06 0.45 0.808 0.529 0.899 
rs10830963 MTNR1B G/C 0.28 0.001 0.003 0.006 0.07 0.134 0.035 0.222 
rs11248914 ITFG3 C/T 0.35 0.011 0.229 0.055 0.36 0.067 0.354 0.485 
rs11558471 SLC30A8 G/A 0.32 0.005 8.2E-05 0.010 0.09 0.309 0.176 0.989 
rs11603334 ARAP1 A/G 0.16 0.005 0.078 0.228 0.06 0.788 0.950 0.734 
rs11708067 ADCY5 G/A 0.23 0.070 0.001 0.034 0.16 0.002 0.003 0.074 
rs11954649 SOX30 G/C 0.00 NA NA NA 0.05 0.812 0.220 0.184 
rs11964178 C6orf183 G/A 0.43 0.861 0.844 0.702 0.36 0.180 0.748 0.475 
rs12621844 FOXN2 C/T 0.39 0.732 0.294 0.358 0.84 0.829 0.853 0.666 
rs12819124 RP1 A/C 0.47 0.765 0.930 0.001 0.21 0.500 0.826 0.146 
rs13134327 FREM3 A/G 0.32 0.800 0.662 0.031 0.30 0.220 0.854 0.772 
rs1402837 G6PC2 T/C 0.22 0.016 9.3E-05 2.7E-07 0.31 0.471 0.728 0.656 
rs1558902 FTO A/T 0.41 0.545 0.017 0.131 0.11 0.065 0.176 0.514 
rs17509001 ATAD2B C/T 0.14 0.309 0.152 0.027 0.09 0.604 0.524 0.802 
rs17533903 MYO9B A/G 0.21 0.577 0.167 5.0E-04 0.24 0.403 0.232 0.689 
rs17747324 TCF7L2 C/T 0.23 1.7E-04 3.2E-05 1.8E-04 0.07 0.396 0.755 0.890 
rs1800562 HFE A/G 0.06 0.337 0.128 0.001 0.01 0.846 0.670 0.146 
rs198846 HFE A/G 0.16 0.390 0.198 0.123 0.88 0.533 0.270 0.260 
rs2110073 PHB2 T/C 0.10 0.321 0.938 0.002 0.42 0.177 0.349 0.160 
rs2383208 MTAP G/A 0.18 0.008 0.019 0.007 0.19 0.293 0.763 0.596 
rs2408955 SENP1 G/T 0.48 0.567 0.879 0.002 0.63 0.813 0.824 0.632 
rs267738 CERS2 G/T 0.21 0.444 0.434 0.511 0.04 0.853 0.745 0.297 
rs2779116 SPTA1 T/C 0.27 0.714 0.792 9.9E-06 0.22 0.111 0.167 0.961 
rs282587 ATP11A G/A 0.12 0.586 0.248 1.0E-04 0.69 0.050 0.142 0.246 
rs3824065 GCK T/C 0.42 3.3E-04 0.002 0.125 0.24 0.086 0.134 0.910 
rs4607517 GCK A/G 0.17 2.0E-04 0.003 5.7E-05 0.11 0.088 0.097 0.244 
rs4737009 ANK1 A/G 0.24 0.126 0.515 0.018 0.46 0.274 0.461 0.361 
rs4745982 HK1 G/T 0.07 0.190 0.263 5.8E-06 0.10 0.889 0.921 0.602 
rs4820268 TMPRSS6 G/A 0.46 0.264 0.350 0.010 0.72 0.073 0.029 0.181 
rs560887 G6PC2 T/C 0.30 0.080 0.003 0.003 0.95 0.811 0.583 0.861 
rs579459 ABO C/T 0.23 0.268 0.340 0.001 0.13 0.210 0.487 0.600 
rs592423 CITED2 A/C 0.46 0.514 0.535 0.063 0.61 0.323 0.605 0.333 
rs6474359 ANK1 C/T 0.03 0.979 0.486 4.3E-04 0.27 0.077 0.047 0.879 
rs6980507 SLC20A2 A/G 0.39 0.256 0.873 0.015 0.48 0.514 0.557 0.663 
rs7040409 C9orf47 G/C 0.07 0.499 0.765 0.001 0.26 0.028 0.005 0.115 
rs7616006 SYN2 G/A 0.43 0.705 0.385 0.181 0.36 0.974 0.959 0.836 
rs761772 TMC6 C/T 0.13 0.077 0.109 0.009 0.13 0.480 0.361 0.861 
rs7756992 CDKAL1 G/A 0.27 0.180 0.094 0.292 0.42 0.856 0.997 0.995 
rs8192675 SLC2A2 C/T 0.30 5.4E-05 6.1E-05 0.010 0.29 0.232 0.239 0.024 
rs837763 CDT1 C/T 0.44 0.591 0.804 0.046 0.56 0.492 0.554 0.533 
rs857691 SPTA1 T/C 0.25 0.803 0.492 5.6E-06 0.30 0.092 0.226 0.894 
rs9604573 GAS6 A/G 0.26 0.482 0.300 0.687 0.24 0.902 0.833 0.425 
rs9818758 USP4 A/G 0.17 0.240 0.870 0.780 0.09 0.297 0.297 0.642 
rs9914988 ERAL1 G/A 0.21 0.307 0.993 0.058 0.66 0.252 0.080 0.342 
*Candidate SNPs selected from NHGRI database based on previous genome-wide significant associations 
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†P-values that reach study-wide significance for fructosamine and glycated albumin, p<2.7x10-4 








*Fructosamine is log transformed.  
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*Fructosamine is log transformed. 
†Included SNPs with MAF ≥5% and imputation quality (INFO) ≥0.8, insertions and deletions 
excluded 
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Supplemental Table 3.1. Characteristics of participants included in the GWAS* 
 ARIC CARDIA 
 Blacks Whites Blacks Whites 
N 2,104 (22%) 7,647 (78%) 608 (32%) 1,304 (68%) 
Age 56 (6) 57 (6) 45 (4) 46 (3) 
Male 782 (37%) 3502 (46%) 230 (38%) 604 (46%) 
ARIC site 
  Forsyth County, NC 
  Jackson, MS 
  Minneapolis, MN 
  Washington County, MD 
CARDIA site 
   Birmingham, AL 
   Chicago, IL 
   Minneapolis, MN 









































Fasting glucose (mg/dL)† 109 (25) 104 (17) 95 (11) 95 (11) 






5.3 (0.3);  
34 (3.3) 
Fructosamine (µmol/L) 238 (35) 227 (23) 227 (21) 225 (18) 
Percent glycated albumin (%) 14 (3) 13 (2) 13 (1) 13 (1) 
Serum albumin (g/dL) 4.1 (0.3) 4.2 (0.3) 4.1 (0.3) 4.3 (0.3) 
Undiagnosed diabetes§ 226 (11%) 418 (5%) - - 
*Continuous variables shown as mean (SD) and categorical variables shown as n (%) 
†ARIC fasting glucose N=9,574 
‡ARIC HbA1c N=9,626 
§Undiagnosed diabetes defined as fasting glucose ≥126 mg/dL if fasting for ≥8 hours or fasting glucose 
>200 if not fasting for ≥8 hours 
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Supplemental Table 3.2. Power for replication of ARIC genome-wide significant results 
in CARDIA and across race in ARIC.* 
SNP Closest Gene Outcome Cohort Race N 
Mean 
(SD) RAF† Beta Power 
rs34459162 RCN3 Fructosamine (umol/L) CARDIA White 1304 5.41 (0.08) 0.09 0.02 0.96 
rs1260326 GCKR Percent glycated albumin (%) 
CARDIA White 1304 2.53 (0.09) 0.43 0.01 0.80 
ARIC Black 2104 2.60 (0.14) 0.14 0.000
3 
0.05 
rs2438321 CNTN5 Fructosamine (umol/L) 
CARDIA Black 608 5.42 (0.09) 0.06 0.006 0.09 
ARIC White 7647 5.41 (0.09) 0.24 0.001 0.09 
*Power calculations were done in Quanto (http://biostats.usc.edu/Quanto.html). Quanto 
assumptions: continuous trait, gene only, additive inheritance, alpha=0.05 for replication. 
†RAF=risk allele frequency 
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Supplemental Table 3.3. Association result for top fructosamine and percent glycated 
albumin SNPs after excluding samples with undiagnosed diabetes in ARIC (N 
whites=7,229; N blacks=1,878) *,†,‡ 
     Fructosamine (µmol/L) Percent glycated albumin (%) 




freq§ Beta (SE) P-value Beta (SE) P-value 
rs34459162 RCN3 C/T 
White 0.08 -0.02 (0.003) 6.8E-10 -0.02 (0.003) 1.3E-8 
Black - - - - - 
rs1260326 GCKR T/C White 0.41 -0.002 (0.001) 0.10 -0.01 (0.002) 4.7E-9 Black 0.15 -0.003 (0.004) 0.52 -0.005 (0.005) 0.32 
rs2438321 CNTN5 G/A White 0.24 -0.001 (0.002) 0.74 0.002 (0.002) 0.30 Black 0.11 0.02 (0.005) 4.2E-5 0.01 (0.005) 0.18 
rs59443763 PRKCA C/T White - - - - - Black 0.06 0.02 (0.006) 0.01 0.03 (0.007) 1.1E-4 
*Undiagnosed diabetes defined as fasting glucose ≥126 mg/dL if fasting for ≥8 hours or fasting glucose 
>200 if not fasting for ≥8 hours 
†Genome-wide significant results are in bold 
‡Fructosamine and percent glycated albumin are log transformed 
§A1 is minor allele in whites 
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Supplemental Table 3.4. Association results for top SNPs with serum albumin 
(N=7,586) *,† 
SNP Closest Gene A1/A2‡ Race A1 freq Beta (SE) P-value 
rs34459162 RCN3 C/T White 0.08 -0.003 (0.002) 0.17 Black - - - 
rs1260326 GCKR C/T White 0.40 0.003 (0.001) 0.01 Black 0.14 0.002 (0.003) 0.57 
rs2438321 CNTN5 G/A White 0.24 -0.002 (0.001) 0.15 Black 0.11 0.01 (0.004) 0.002 
rs59443763 PRKCA C/T White - - - Black 0.06 -0.004 (0.005) 0.41 
*Bonferroni corrected significance threshold (0.05/(4 SNPs * 2 races) = 0.006) results are in bold 
†Serum albumin is log transformed 
































(mg/dL) HbA1c (%) 














Total glycated albumin 
(g/dL) 





  -- 0.47 (0.42) 0.26 
HbA1c (%)     -- 
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Supplemental Table 3.6. Beta and standard errors for associations between fasting 
glucose known genetic determinants and fructosamine and percent glycated albumin in 
ARIC*† 
  Whites Blacks 





































































(0.006) 0 (0.007) 
0.988 
(1.273) 




























































































(1.246) 0.003 NA NA NA 








































































(0.004) 0 (0.005) 
-0.03 
(0.926) 









































































































































































































(0.005) 0 (0.006) 
-0.135 
(1.035) 























*Candidate SNPs selected from NHGRI database based on previous genome-wide significant associations 
†P-values that reach study-wide significance for fructosamine and glycated albumin, p<3.0x10-4 




Supplemental Table 3.7. Beta and standard errors for associations between HbA1c 
known genetic determinants and fructosamine and percent glycated albumin in ARIC* 
  Whites Blacks 









































































































































































































































































































































































































































(0.004) 0 (0.005) 
-0.006 
(0.028) 

















(0.004) 0 (0.004) 
0 
(0.026) 

































































*Candidate SNPs selected from NHGRI database based on previous genome-wide significant associations 
†P-values that reach study-wide significance for fructosamine and glycated albumin, p<2.7x10-4 
(0.05/(2*2*46)) are in bold; P-values that reach nominal significance (p<0.05) for HbA1c are in bold 
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Supplemental Table 3.8. Pearson’s correlation coefficients among glycemic 
biomarkers.† 
 Fasting glucose 
(mg/dL) 




 W B Total W B Total W B Total W B Total 
HbA1c (%; 
mmol/mol) 
0.69 0.77 0.72          
Fructosamine 
(µmol/L) 
0.52 0.68 0.58 0.45 0.61 0.53       
Percent glycated 
albumin (%) 
0.54 0.61 0.59 0.53 0.69 0.61 0.76 0.84 0.79    
Total glycated 
albumin (g/dL) 
0.53 0.63 0.59 0.47 0.63 0.55 0.85 0.91 0.87 0.93 
 
0.94 0.93 



























Supplemental Table 3.9. Percent variance of HbA1c explained by known glycemic and 
nonglycemic SNPs associated with HbA1c* 
Source Gene SNP MAF Beta Var(SNP) Variance explained† 
Erythrocytic       
Wheeler TMEM79 rs12132919 0.29 0.01 0.41 4.2E-05 
Wheeler SPTA1 rs857691 0.25 0.04 0.38 0.003 
Wheeler HK1 rs4745982 0.07 -0.08 0.13 0.003 
Wheeler CNTN5 rs11224302 0.10 -0.05 0.18 0.002 
Wheeler ATXN2 rs10774625 0.48 0.02 0.50 0.001 
Wheeler SENP1 rs2408955 0.48 0.03 0.50 0.001 
Wheeler ITFG3 rs11248914 0.35 -0.02 0.45 0.001 
Wheeler CDH3 rs4783565 0.27 0.01 0.39 1.6E-04 
Wheeler CDT1 rs837763 0.44 0.02 0.49 0.001 
Wheeler ERAL1 rs9914988 0.21 0.02 0.33 4.9E-04 
Wheeler MYO9B rs17533903 0.21 0.04 0.33 0.002 
Wheeler TMPRSS6 rs4820268 0.46 -0.02 0.50 0.001 
Wheeler SYN2 rs7616006 0.43 -0.01 0.49 2.5E-04 
Wheeler C6orf183 rs11964178 0.43 0.00 0.49 2.0E-05 
Wheeler CITED2 rs592423 0.45 -0.02 0.50 4.6E-04 
Wheeler + Soranzo HFE rs1800562 0.06 -0.06 0.12 0.002 
Wheeler HFE rs198846 0.16 0.02 0.26 3.3E-04 
Wheeler + Soranzo + 
Chen ANK1 rs4737009 0.24 0.02 0.37 0.001 
Wheeler SLC20A2 rs6980507 0.39 0.02 0.48 0.001 
Wheeler C9orf47 rs7040409 0.07 -0.06 0.12 0.002 
Soranzo + Chen‡  rs1046896 0.31 0.02 0.43 0.001 
Chen MYO9B rs11667918 0.28 -0.02 0.40 0.001 
Soranzo  rs16926246 0.12 -0.09 0.21 0.006 
Soranzo  rs2779116 0.27 0.04 0.39 0.003 
Chen TMEM79 rs6684514 0.29 0.01 0.41 7.7E-05 
Soranzo  rs7998202 0.12 0.05 0.22 0.003 
Soranzo  rs855791 0.43 0.02 0.49 0.001 
Chen HBS1L/MYB rs9399137 0.27 -0.01 0.39 2.2E-04 
Chen CYBA rs9933309 0.28 -0.01 0.41 9.5E-05 
Total      0.034 
Glycemic       
Wheeler TCF7L2 rs17747324 0.23 0.04 0.36 0.002 
Wheeler KCNQ1 rs2237896 0.05 -0.05 0.09 0.001 
Wheeler FADS2 rs174577 0.34 0.00 0.45 4.4E-06 
Wheeler ARAP1 rs11603334 0.16 -0.01 0.27 2.0E-04 
Wheeler MTNR1B rs10830963 0.28 0.03 0.40 0.001 
Wheeler PDX1 rs11619319 0.22 0.03 0.34 0.001 
Wheeler KL rs576674 0.16 0.00 0.27 8.5E-06 
Wheeler G6PC2 rs13387347 0.46 0.02 0.50 0.001 
Wheeler G6PC2 rs560887 0.30 0.03 0.42 0.001 
Wheeler ADCY5 rs11708067 0.23 -0.02 0.35 0.001 
Wheeler SLC2A2 rs8192675 0.30 -0.02 0.42 0.001 
Wheeler FREM3 rs13134327 0.32 0.02 0.44 0.001 
Wheeler CDKAL1 rs7756992 0.27 0.01 0.40 1.5E-04 
Wheeler DGKB rs2191349 0.47 0.01 0.50 3.6E-04 
Wheeler GCK rs4607517 0.17 0.04 0.28 0.002 
Wheeler GCK rs3824065 0.42 -0.01 0.49 3.6E-04 
Wheeler SLC30A8 rs11558471 0.32 -0.02 0.43 0.001 
Wheeler ABO rs579459 0.23 0.03 0.35 0.002 
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Wheeler MTAP rs2383208 0.18 -0.03 0.30 0.001 
Soranzo MTNR1B rs1387153 0.29 0.03 0.41 0.001 
Soranzo + Chen GCK rs1799884 0.17 0.04 0.28 0.002 
Chen G6PC2/ABCB11 rs3755157 0.11 -0.01 0.20 3.6E-05 
Soranzo G6PC2 rs552976 0.35 -0.03 0.45 0.002 
Chen CDKAL1 rs7772603 0.27 0.01 0.39 3.0E-04 
Total      0.021 
Unclassified       
Wheeler CERS2 rs267738 0.21 -0.01 0.33 5.8E-05 
Wheeler SYF2 rs2375278 0.17 -0.01 0.28 2.5E-04 
Wheeler HK1 rs10823343 0.26 -0.05 0.38 0.003 
Wheeler PHB2 rs2110073 0.10 0.04 0.18 0.001 
Wheeler ATP11A rs282587 0.12 -0.05 0.21 0.002 
Wheeler GAS6 rs9604573 0.26 0.00 0.38 2.5E-05 
Wheeler FTO rs1558902 0.41 0.01 0.48 3.1E-04 
Wheeler TMC6 rs2073285 0.21 0.01 0.33 9.8E-05 
Wheeler FN3KRP rs1046896 0.31 0.02 0.43 0.001 
Wheeler MYO9B rs11086054 0.31 -0.02 0.42 4.0E-04 
Wheeler SCRN3 rs17256082 0.34 0.02 0.45 0.001 
Wheeler ATAD2B rs17509001 0.14 0.03 0.24 0.001 
Wheeler FOXN2 rs12621844 0.39 0.01 0.47 1.2E-04 
Wheeler FNDC3B rs4894799 0.38 0.00 0.47 3.6E-05 
Wheeler USP4 rs9818758 0.17 0.00 0.28 1.1E-05 
Wheeler + Soranzo§ ANK1 rs6474359 0.03 -0.09 0.06 0.002 
Wheeler KLF4 rs1467311 0.34 0.00 0.45 2.8E-07 
Total      0.012 
 
*All variants come from Chen 201412 and Soranzo 201011 which identified “glycemic” and “nonglycemic” 
SNPs.  Wheeler 2017 designated SNPs as “erythrocytic”, “glycemic” or “unclassified” 
†Variance explained was calculated using the equation: Ri2 = bi2 x var(SNPi)/var(y) where bi = the effect 
size of the association between the SNPi and the phenotype y, var(SNPi) is 2 x MAFSNPi x (1-MAFSNPi) and 
var(y) is the variance in the phenotype (variance in HbA1c in ARIC=0.25)  
‡Chen SNP: rs1046875, r2=1 with rs1046896 




Supplemental Figure 3.1. Selection of participants 
 







































Supplemental Figure 3.8. Manhattan plot for GWAS of percent glycated albumin* in 
whites (N=7,647). 
 






Supplemental Figure 3.9. Regional association plot for rs1260326 and percent glycated 






Supplemental Figure 3.10. Manhattan plot for meta-analysis of black and white ARIC 
participants for percent glycated albumin (N=9,751) 
 
 





Supplemental Figure 3.11. Manhattan plot for GWAS of fructosamine* in blacks 
(N=2,104) 
 









Supplemental Figure 3.13. Manhattan plot for meta-analysis of black and white ARIC 
participants for fructosamine (N=9,751) 
 
*Fructosamine is natural log transformed 
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Supplemental Figure 3.15. Regional association plot of rs59443763 and percent 
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Fructosamine and glycated albumin are nontraditional type 2 diabetes biomarkers 
that can be used for diabetes diagnosis and management.  These biomarkers are under 
genetic control, and a previous genome-wide association study in the Atherosclerosis 
Risk in Communities (ARIC) Study identified several variants associated with 
fructosamine and glycated albumin.  To take advantage of the correlation between these 
two biomarkers and increase power over the single phenotype analysis to detect 
additional variants associated with fructosamine and glycated albumin, we implemented a 
multivariate phenotype analysis using the program Unified Score-based Association Test 
(USAT).  We jointly analyzed fructosamine and glycated albumin among European 
American (N=7,395) and African American (N=2,309) participants in ARIC using both 
genotype and exome sequencing data.  Among individuals of European ancestry, variants 
in the UGT1A region were associated with a joint fructosamine-glycated albumin 
phenotype (top SNP rs887829, p=3.18x10-8) that was not identified in the single 
phenotype analyses.  No additional loci were identified in African ancestry individuals 
using this multivariate analysis. The use of a multivariate phenotype identified a new 
locus, UGT1A for fructosamine and glycated albumin, and further research is warranted 








Type 2 diabetes is defined by hyperglycemia, or elevated blood glucose 
concentrations. Hyperglycemia is commonly measured by fasting glucose and HbA1c, 
but due to limitations of these biomarkers, nontraditional biomarkers such as 
fructosamine and glycated albumin have been proposed.1-7  Fructosamine, which is 
glucose bound to total serum protein, and glycated albumin, which is glucose bound to 
the most prevalent serum protein, albumin, reflect average blood glucose over the 
previous 2-3 weeks.8  
  It is well established that genetics play a role in type 2 diabetes and traditional 
measures of hyperglycemia.  Large studies evaluating fasting glucose and HbA1c 
(sample sizes up to 133,000-160,000) have identified many variants associated with these 
measures (fasting glucose (n=36) and HbA1c (n=60)).9,10 Our recent genome-wide 
association study (GWAS) also identified several genetic variants associated with 
fructosamine and glycated albumin: a known type 2 diabetes variant in GCKR associated 
with glycated albumin and a variant in RCN3 associated with fructosamine, possibly in a 
nonglycemic manner (Chapter 3).  However, these variants only explain 0.3 to 0.6% of 
the variance of glycated albumin (h2=0.45) and fructosamine (h2=0.44), respectively, 
among people of European ancestry (Chapter 2,3).  This may be due to the limited 
sample sizes of this study (N=7,229).  
One way to achieve additional power is through multivariate phenotype 
analysis,11,12 which aims to jointly analyze multiple phenotypes (e.g., multiple biomarkers 
of hyperglycemia) by taking into account the correlation structure of the phenotypes.  
This phenotypic correlation structure is ignored in univariate analyses, which is 
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equivalent to discarding this information.  We used the method Unified Score-based 
Association Test (USAT)13 to evaluate the association between genetic variants and 
biomarkers of hyperglycemia in the Atherosclerosis Risk in Communities (ARIC) Study.  
USAT is a data-adaptive test of association of multiple continuous phenotypes with a 
single genetic variant. We performed multivariate phenotype analysis using both GWAS 
data, which captures common variants, and exome sequencing data, which captures rare 
coding variants, to identify additional variants associated with fructosamine and glycated 




  The ARIC study is a longitudinal cohort study initiated in 1987 to examine 
cardiovascular disease risk factors in 15,792 middle-aged adults from four study sites: 
Jackson, Mississippi; Forsyth, North Carolina; Washington County, Maryland; and 
suburban Minneapolis, Minnesota.14   Participants attended a baseline visit in 1987-1989 
with six subsequent visits and a seventh currently ongoing.  Study participants provided 
informed consent and protocols were approved by relevant institutional review boards. 
 This analysis was limited to individuals who had genotyping or exome 
sequencing data available.   Of the 14,348 individuals who attended ARIC visit 2, 
individuals were excluded if they had diagnosed diabetes (N=1,256), missing diabetes 
status (N=4), or missing fructosamine or glycated albumin measures (N=929; 
Supplemental Figure 4.1). A total of 9,411 (N=7,395 European ancestry individuals and 
2,016 African ancestry individuals) were genotyped and passed quality control, and a 
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total of 8,899 individuals (N=6,590 European ancestry individuals, 2,309 African 
ancestry individuals) were exome sequenced and passed quality control.  
Genotyping 
 Samples were genotyped on the Affymetrix 6.0 array and imputed to 1000 
Genomes Phase I (March 2012) using IMPUTE2.  Poor quality samples were excluded 
due to sex mismatches, genetic outliers, failed concordance with Taqman genotypes, 
first-degree relatedness with another study member and missingness>98%.  SNPs with 
missingness>5%, Hardy-Weinberg Equilibrium (HWE)<0.00001, or low minor allele 
frequency (MAF) <0.005 were excluded.  Indels, SNPs with duplicated basepair 
positions, imputation quality info score<0.8 and minor allele frequency (MAF)<0.05 
were also excluded.  Imputed dosages were converted to hardcalls (A,T,G,C) for analysis 
in USAT.  The final dataset included 6,792,306 SNPs in the European ancestry sample 
and 5,313,666 SNPs in the African ancestry sample. 
Exome sequencing and Quality Control 
 DNA was extracted from blood collected at visit 1 from ARIC participants.  All 
sequencing was done as part of the CHARGE consortium at the Baylor College of 
Medicine Human Genome Sequencing Center (HGSC).  Samples were sequenced on the 
Illumina HiSeq 2000 or 2500 platform (San Diego, CA), and quality control measures 
implemented.  Single nucleotide variants (SNVs) were excluded if they met any of the 
following criteria: posterior probability<0.95, variant read count <3, variant read ratio 
<0.25 or >0.75, strand bias >99% in single direction, total convergence <10 fold for 
SNVs (<30x for indels), outside exon capture regions, monomorphic variant, missing rate 
>20%, mappability score <0.8, mean depth coverage >500 fold, Hardy Weinberg 
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Equilibrium p<5x10-6 in ancestry-specific groups.  Samples were excluded if they had 
>20% missing data or beyond 6 standard deviations from the mean read depth, singleton 
count, heterozygote to homozygote ratio, or transition to transversion (Ti/Tv) ratio.  The 
post quality control sample included 7,810 European Ancestry individuals and 3,180 
African Ancestry individuals with genetic data on 2,556,859 SNVs and 76,133 indels.  In 
addition, we further excluded variants with less than 10 copies of the minor allele 
(MAF<0.008 (10/(6,590*2)) for the European ancestry sample and MAF<0.002 
(10/(2,309*2) for the African ancestry sample).   
Hyperglycemia biomarkers 
 All biomarkers were measured from serum samples collected at visit 2 (1990-
1992). Samples were stored at -70°C and fructosamine (Roche Diagnostics, Indianapolis 
IN, USA) and glycated albumin (GA-L Asashi Kasei Pharma Corporation, Tokyo, Japan) 
were measured in 2012-2013 using a Roche Modular P800 system.  
Statistical Analysis 
Values for all biomarkers were natural log transformed for statistical analyses to 
account for skewed distributions.  We calculated residuals based on models controlling 
for age, sex, ARIC study site and the top 10 principal components, and used the residuals 
as phenotypes in all analyses. 
Multivariate analysis 
 We implemented the program USAT (v1.21, 
https://github.com/RayDebashree/USAT), which has high power to detect association in 
a variety of variant-phenotype association settings that is lacking in other multivariate 
methods.13,15  For a given genetic variant, USAT gives weights to two types of 
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multivariate phenotype methods: MANOVA (based on a multivariate linear regression 
model) and a marginal score test (based on univariate regression models).  It then 
adaptively selects the weighted test with minimum p-value and computes an approximate 
asymptotic p-value of association.13,15  
We ran USAT using an additive genetic model testing one variant at a time 
separately by ancestry.  We evaluated common variants using genotype data, and rare, 
coding variants using exome sequencing data combining the phenotypes fructosamine 
and glycated albumin. 
Univariate analysis 
 To determine the association between the variants and the biomarkers individually 
using genotype data, we performed linear regression analysis of all variants using an 
additive genetic model on biomarker residuals using PLINK v1.9 separately by 
ancestry.16  We accounted for multiple testing of the two phenotypes by using a 
significance threshold of 2.5x10-8=5x10-8/(2 biomarkers).  
 We also evaluated the association of exome sequencing variants with fructosamine 
and glycated albumin, separately by ancestry using the R program SeqMeta.  We used an 
additive genetic model and the biomarker residuals.  We accounted for multiple 
comparisons by using a Bonferroni corrected significance threshold of (2.1x10-
7=0.05/(121,052 variants * 2 biomarkers) for European ancestry, 1.4x10-7=0.05/(175,583 





This analysis included European ancestry individuals: 7,395 with genotype data 
and 6,590 with exome sequencing data, and African ancestry individuals: 2,016 with 
genotype data and 2,309 with sequencing data.  Over half were female, and the mean age 
was 56-57 years.  Values for all glycemic biomarkers were higher among African 
ancestry individuals than European ancestry individuals (Supplemental Table 4.1).  
Correlations among biomarkers were moderate (r=0.52 between HbA1c and 
fructosamine) to strong (r=0.79 for fructosamine and glycated albumin) and were similar 
in the genotyped and exome sequenced samples (Supplemental Table 4.2).  
Multivariate phenotype analysis  
 Among European ancestry individuals, the joint analysis using genotype data of 
fructosamine and glycated albumin identified variants on chromosome 2 in the UGT1A 
region (top SNP rs887829, p=3.18x10-8; Table 4.1) that were not significant in the single 
phenotype analysis for either fructosamine (p=6.04x10-6) or glycated albumin (p=0.72).  
Using the exome sequencing data, no variants were significantly associated with the joint 
fructosamine-glycated albumin phenotype (Table 4.2), however variants in LD (r2=0.75) 
with the UGT1A1 variants identified with the genotype data neared significance 
(rs1105880, p=1.83x10-5) in the exome multivariate analysis.   
The variant in GCKR significantly associated with glycated albumin in our 
univariate GWAS using imputed data (rs1260326) approached significance in both the 
genotype (p=8.60x10-8) and exome sequencing (p=1.61x10-5) multivariate analysis 
(Tables 4.1, 4.2).  The variant associated with fructosamine in our previous GWAS 
(rs34459162) approached significance in the exome sequencing multivariate analysis 
(p=2.56x10-7, Table 4.2). 
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 Among African ancestry individuals, genotype multivariate analysis identified 
two regions on chromosome 11: a variant in the ARAP1/STARD10 (p=1.88x10-8; Table 
4.3) and an intergenic variant (rs2438321, p=3.06x10-8), as well a region on chromosome 
17 in PRKCA (p≥1.88x10-8) associated with the joint fructosamine-glycated albumin 
phenotype.  The rs2438321 SNP was associated with fructosamine (p=2.65x10-9) and the 
ARAP1/STARD10 (p=2.03x10-8) and PRKCA variants (p≥3.78x10-9) were associated 
with glycated albumin in the univariate GWAS using imputed data.  Multivariate analysis 
using sequencing data did not produce any variants significantly associated with the 
fructosamine-glycated albumin joint phenotype. 
Single phenotype analysis 
 Among European ancestry individuals, no variants were genome-wide 
significantly associated with fructosamine or glycated albumin using the genotyped data 
(Supplemental Table 4.3).  For fructosamine, the significant SNP in our previous 
GWAS in RCN3, rs34459162 neared significance (p=1.96x10-6) and was in linkage 
disequilibrium (LD) with the most significant SNP in this analysis (rs111981233, 
r2=0.67, p=1.75x10-7).  For glycated albumin, the significant SNP in our previous GWAS 
in GCKR, rs1260326, also approached significance (p=6.22x10-8).  One variant in the 
European ancestry sample reached exome-wide significance in the univariate analysis 
(rs34459162, p=2.19x10-7; Supplemental Table 4.4), which was also identified by our 
previous GWAS. One variant was associated with glycated albumin among European 
ancestry individuals (rs184161698, 1.43x10-7; Supplemental Table 4.4).   
 In African ancestry individuals, variants in an intergenic region on chromosome 
11 including the SNP from our original GWAS, rs2438321 (p=2.65x10-9) and a variant 
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on chromosome 2 (rs10490265, p=1.59x10-8) were associated with fructosamine using 
the genotype data, (Supplemental Table 4.4).  A region on chromosome 17 (top SNP: 
rs74617220, p=3.78x10-9) which included the SNP from our previous GWAS near 
PRKCA and a variant on chromosome 11 (p=2.03x10-8) was associated with glycated 
albumin.   Using the exome sequencing data, a variant in COL19A1 (rs140658141, 
p=1.21x10-7; Supplemental Table 4.6) was associated with fructosamine, and two 
variants were associated with glycated albumin (rs115081997, p=6.03x10-8; 
rs149541658, p=1.12x10-7; Supplemental Table 4.6). 
 
4.5 Discussion 
 Among European ancestry individuals, the multivariate phenotype analysis of 
fructosamine and glycated albumin using common and low-frequency variants identified 
variants in the UGT1A region that was not significant in the univariate analysis of 
fructosamine or glycated albumin.  Exome sequencing analysis also identified variants in 
this same region approaching significance.  The UGT1A region is a complex of 
alternatively spliced genes including UGT1A11, 1A3, 1A4, 1A5, 1A6, 1A7, 1A8, 1A9 and 
1A10 (RefSeq: https://www.ncbi.nlm.nih.gov/nuccore/NM_000463.2).  These genes are 
involved in the glucuronidation of bilirubin (a product of heme catabolism), which 
creates water-soluble bilirubin.  UGT1A variants cause the hereditary unconjugated 
hyperbilirubinemias Crigler-Najjar syndromes and Gilbert syndrome.17  In addition, 
variants in UGT1A are associated with bilirubin levels among individuals without these 
syndromes.18-20  Moderately elevated bilirubin is associated with a decreased risk of 
diabetes and cardiovascular disease.21-23 In addition, bilirubin can also bind to albumin.24   
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In the single phenotype analysis, the variants in UGT1A show suggestive significance 
with fructosamine, measured as a concentration that does not account for total serum 
protein. In contrast, variants in UGT1A were not associated with glycated albumin, which 
is expressed as the percent, accounting for total serum albumin. Because the multivariate 
phenotype results are likely driven by the fructosamine association, and fructosamine 
levels are more affected by serum albumin levels, it may be that the multivariate 
phenotype association is impacted by an albumin-related pathway rather than a diabetes-
related pathway.  If variants in UGT1A affect bilirubin homeostasis, this could alter the 
amount of albumin bound to bilirubin, which would then impact the amount of albumin 
available to be glycated, thus impacting fructosamine levels.  
The joint analyses using genotype and exome sequencing data support the 
findings from our previous univariate GWAS using imputed data, identifying all of the 
same regions as the GWAS: GCKR, RCN3, PRKCA and an intergenic region on 
chromosome 11.  The minor differences in the single phenotype analysis presented here 
from our previous GWAS are likely due to the slightly different sample (this analysis was 
restricted to individuals who had complete data on all biomarkers), the differences in data 
(imputed dosages vs imputed data converted to hard calls), as well as the program used 
for analysis (SNPTEST vs PLINK).  The variants associated with fructosamine and 
glycated albumin in European ancestry individuals in our original GWAS were very close 
to genome-wide significance in this analysis, and the variants found in African ancestry 
individuals in the original GWAS were also found to be associated in this analysis. 
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 All of the significant associations from the joint modeling of fructosamine and 
glycated albumin using the genotyping data in the African ancestry sample were 
previously identified in the univariate phenotype analysis of fructosamine or glycated 
albumin.  Joint analysis using the exome sequencing data did not result in significant 
associations in either the European ancestry or African ancestry sample.  
 Multivariate phenotype analysis successfully demonstrated increased power to 
detect genetic associations with fructosamine and glycated albumin among European 
ancestry individuals, by identifying variants in UGT1A1 not significantly associated in 
single phenotype analysis.  This is an important method, particularly for phenotypes like 
fructosamine and glycated albumin that are not regularly collected in epidemiologic 







4.6 Tables and Figures 
 
Table 4.1. Multivariate phenotype analysis results using genotype data among European 
ancestry individuals. 





rs887829 2 T UGT1A12 3.18E-08 6.04E-06 0.72 
rs4148325 2 T UGT1A1 3.52E-08 9.72E-06 0.83 
rs4148324 2 G UGT1A1 4.83E-08 1.18E-05 0.83 
rs6742078 2 T UGT1A1 5.56E-08 1.20E-05 0.82 
rs59774409 19 T FCGRT 5.83E-08 2.75E-07 2.50E-07 
rs111981233 19 G FCGRT 7.87E-08 1.75E-07 5.38E-07 
rs1260326 2 T GCKR 8.60E-08 0.02 6.22E-08 
rs111741722 2 G UGT1A1 9.62E-08 1.48E-05 0.81 
rs780093 2 T GCKR 1.33E-07 0.03 1.14E-07 
rs780094 2 T GCKR 2.56E-07 0.04 2.13E-07 
1Significant results are in bold.  Significance threshold: p<5x10-8 for multivariate results,  
5x10-8/(2 biomarkers)=2.5x10-8 for univariate results. 





Table 4.2. Multivariate phenotype analysis results using exome sequencing data among 
European ancestry individuals. 






rs34459162 19 RCN3 T 0.07 2.56E-07 2.19E-07 7.56E-07 
rs34654230 19 RCN3 C 0.07 6.96E-07 5.14E-07 2.05E-06 
rs3187346 19 RCN3 T 0.07 1.54E-06 1.49E-06 1.70E-06 
rs1129459 19 RCN3 C 0.07 1.71E-06 1.18E-06 4.34E-06 
rs116604830 12 CCDC63 G 0.02 1.99E-06 9.15E-07 0.0005 
rs28929474 14 SERPINA1 C 0.02 5.71E-06 0.92 0.0003 
rs8105626 19 RCN3 T 0.07 8.84E-06 5.77E-06 2.19E-05 
rs2878342 19 FCGRT C 0.08 1.28E-05 1.44E-05 5.08E-06 
rs1260326 2 GCKR T 0.59 1.61E-05 0.02 2.94E-06 
rs1105880 2 UGT1A6 A 0.35 1.83E-05 9.96E-05 0.56 
1RAF=risk allele frequency of A1 
2Significant results are in bold.  Significance threshold: 0.05/(121,052 variants * 2 
biomarkers)=4.1x10-7 for multivariate results, 0.05/(121,052 variants * 2 biomarkers)= 
2.1x10-7 for univariate results. 
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Table 4.3. Multivariate phenotype analysis results using genotype data among African 
ancestry individuals. 






rs116714277 11 T STARD10 1.83E-08 1.19E-07 2.03E-08 
rs59443763 17 C PRKCA 1.88E-08 1.04E-06 3.79E-09 
rs59337138 17 T PRKCA 2.15E-08 1.41E-06 3.78E-09 
rs74617220 17 T PRKCA 2.15E-08 1.41E-06 3.78E-09 
rs2438321 11 G intergenic 3.06E-08 2.65E-09 1.52E-05 
rs58597349 17 T PRKCA 3.78E-08 1.88E-06 7.57E-09 
rs58769090 17 T PRKCA 3.78E-08 1.88E-06 7.57E-09 
rs73336540 17 C PRKCA 3.78E-08 1.88E-06 7.57E-09 
rs73336524 17 G PRKCA 6.11E-08 2.42E-06 1.35E-08 
rs1348516 11 G intergenic 6.21E-08 5.60E-09 2.37E-05 
1Significant results are in bold.  Significance threshold: p<5x10-8 for multivariate results,  




Table 4.4. Multivariate phenotype analysis results using exome sequencing data among 
African ancestry individuals. 
SNP Chr Nearest Gene A1 RAF






rs115081997 2 DNAH7 A 0.005 7.77E-07 4.86E-05 6.03E-08 
rs149541658 19 SLC27A5 G 0.009 1.44E-06 8.45E-05 1.12E-07 
rs9937169 16 PKD1L2 T 0.052 1.09E-05 1.91E-05 0.08 
rs237025 6 SUMO4 G 0.717 1.16E-05 5.12E-06 0.001 
rs143807085 2 ITGA4 A 0.010 1.49E-05 3.55E-05 0.13 
rs73265846 5 PCDHGB3 C 0.016 3.10E-05 1.43E-05 0.004 
rs77605839 11 FCHSD2 A 0.028 3.11E-05 1.62E-05 0.0002 
rs16925431 9 DMRT1 T 0.076 3.64E-05 1.71E-05 0.002 
rs16931976 11 OR51B5 T 0.061 5.69E-05 3.47E-05 6.71E-05 
rs2292324 16 NECAB2 C 0.453 6.53E-05 3.11E-05 0.001 
1RAF=risk allele frequency of A1 
2Bonferroni corrected significance threshold = 1.4x10-7 (0.05/(175,583 variants * 2 
biomarkers)), significant results are in bold  
2Significant results are in bold.  Significance threshold: 0.05/175,583 variants =2.8x10-7 




Supplemental Table 4.1. Demographic and clinical characteristics of study participants1 














Female  54% 63% 55% 63% 
Age 57 (5.7) 56 (5.7) 57 (5.6) 56 (5.7) 
Fructosamine 
(µmol/L)  227 (23) 238 (35) 227 (23) 238 (32) 
Glycated albumin 
(%) 12.6 (1.6) 13.6 (2.6) 12.6 (1.6) 13.6 (2.4) 
HbA1c (%)2 5.4 (0.5) 5.8 (0.8) 5.4 (0.52) 5.8 (0.86) 
Fasting glucose 
(mg/dL) 2 103.9 (17.0) 109.2 (24.8) 104 (17) 109 (26) 
1Continuous variables shown as mean (SD)  
2HbA1c genotyped sample European ancestry N=7,315, African ancestry N=1,976; 
exome sequenced sample European ancestry N=6,524, African ancestry N=2,267.  
Fasting glucose genotyped sample European ancestry N=7,294, African ancestry 









Supplemental Table 4.2. Pearson’s correlations among biomarkers (genotyped sample 
N=9,411, exome sequenced sample N=8,621). 
 Fructosamine (µmol/L) 
Glycated 
Albumin (%) HbA1c (%) 
Fasting Glucose 
(mg/dL) 
Fructosamine (µmol/L) 1    
Glycated Albumin (%) 0.79, 0.80 1   
HbA1c (%) 0.52, 0.55 0.61, 0.64 1  
Fasting Glucose (mg/dL) 0.58, 0.60 0.61, 0.65 0.72, 0.74 1 
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Supplemental Table 4.3. Top single variant results for European ancestry individuals, 
genotyping. 1 
 Fructosamine (µmol/L) 
Chr SNP BP Nearest Gene A1 Beta P-Value 
19 rs111981233 50016479 FCGRT G -0.02 1.75E-07 
19 rs59774409 50016748 FCGRT T -0.02 2.75E-07 
19 rs4075250 50057854 intergenic A -0.01 4.04E-07 
19 rs4594362 50059982 NOSIP G -0.01 5.14E-07 
1 rs17316247 63258549 ATG4C C 0.01 1.66E-06 
19 rs111508578 50027533 FCGRT T -0.02 1.81E-06 
19 rs73586516 50046924 RCN3 G -0.02 1.89E-06 
19 rs1316885 50010907 intergenic C -0.01 1.93E-06 
19 rs113176985 50008951 intergenic T -0.01 1.99E-06 
19 rs80094695 50047487 intergenic C -0.02 2.05E-06 
 Glycated Albumin (%) 
Chr SNP BP Nearest Gene A1 Beta P-Value 
2 rs1260326 27730940 GCKR T -0.01 6.22E-08 
2 rs780093 27742603 GCKR T -0.01 1.14E-07 
7 rs10255211 86124483 intergenic C -0.01 1.53E-07 
2 rs780094 27741237 GCKR T -0.01 2.13E-07 
19 rs59774409 50016748 FCGRT T -0.02 2.50E-07 
19 rs111981233 50016479 FCGRT G -0.02 5.38E-07 
6 rs4897175 126657472 intergenic G 0.01 5.60E-07 
2 rs4665972 27598097 SNX17 T -0.01 9.34E-07 
6 rs576049 126730543 CENPW G 0.01 1.10E-06 
1 rs6663454 63295372 ATG4C A 0.01 1.32E-06 
1Significant results are in bold: 5x10-8/(2 biomarkers)=2.5x10-8 
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Supplemental Table 4.4. Top single variant results for European ancestry individuals, 
exome sequencing. 1 
Fructosamine (µmol/L) 
SNP Gene Chr A1/A2 P-value1 MAF Beta SE 
rs34459162 RCN3 19 T/C 2.19E-07 0.071 -3.41 0.66 
rs34654230 RCN3 19 C/T 5.14E-07 0.073 -3.25 0.65 
rs116604830 CCDC63 12 G/T 9.15E-07 0.017 6.52 1.33 
rs1129459 RCN3 19 C/T 1.18E-06 0.073 -3.16 0.65 
rs3187346 RCN3 19 T/C 1.49E-06 0.072 -3.14 0.65 
rs8105626 RCN3 19 T/C 5.77E-06 0.068 -3.04 0.67 
rs137994820 ARAP3 5 T/C 7.41E-06 0.001 26.13 5.83 
rs76384862 COMT 22 C/T 8.19E-06 0.001 24.90 5.58 
rs184161698 ID1 20 A/T 1.17E-05 0.001 18.95 4.32 
rs139240119 SLC25A25 9 G/T 1.20E-05 0.010 7.30 1.67 
Glycated Albumin (%) 
SNP Gene Chr A1/A2 P-value1 MAF Beta SE 
rs184161698 ID1 20 A/T 1.43E-07 0.001 1.54 0.29 
rs34459162 RCN3 19 T/C 7.56E-07 0.071 -0.22 0.04 
rs202140443 PSMB10 16 T/G 1.30E-06 0.001 1.49 0.31 
rs3187346 RCN3 19 T/C 1.70E-06 0.072 -0.21 0.04 
rs142744907 COG7 16 C/T 1.97E-06 0.001 1.61 0.34 
rs34654230 RCN3 19 C/T 2.05E-06 0.073 -0.21 0.04 
rs1260326 GCKR 2 T/C 2.94E-06 0.407 0.11 0.02 
rs1129459 RCN3 19 C/T 4.34E-06 0.073 -0.20 0.04 
rs2878342 FCGRT 19 C/T 5.08E-06 0.076 -0.20 0.04 
1Significant results are in bold: 0.05/(121,052 variants * 2 biomarkers)= 2.1x10-7 
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Supplemental Table 4.5. Top single variant results for African ancestry individuals, 
genotyping. 
 Fructosamine (µmol/L) 
Chr SNP BP Nearest Gene A1 Beta P-Value1 
11 rs2438321 98500410 intergenic G 0.04 2.65E-09 
11 rs1348516 98495807 intergenic G 0.04 5.60E-09 
11 rs2438322 98500409 intergenic T 0.04 9.10E-09 
11 rs1348518 98495639 intergenic G 0.04 1.07E-08 
2 rs10490265 40979468 LOC101929700 T 0.03 1.59E-08 
11 rs2512816 98490543 intergenic T 0.03 2.73E-08 
11 rs3018601 98508879 intergenic A 0.03 4.14E-08 
11 rs2512863 98507758 intergenic T 0.03 5.12E-08 
11 rs2512825 98513495 intergenic A 0.03 7.10E-08 
2 rs55814013 40982682 LOC101929700 A 0.03 7.84E-08 
 Glycated Albumin (%) 
Chr SNP BP Nearest Gene A1 Beta P-Value1 
17 rs74617220 64515083 PRKCA T 0.05 3.78E-09 
17 rs59337138 64515907 PRKCA T 0.05 3.78E-09 
17 rs59443763 64526988 PRKCA C 0.05 3.79E-09 
17 rs73336540 64499524 PRKCA C 0.05 7.57E-09 
17 rs58769090 64501060 PRKCA T 0.05 7.57E-09 
17 rs58597349 64503204 PRKCA T 0.05 7.57E-09 
17 rs73336524 64489878 PRKCA G 0.05 1.35E-08 
11 rs116714277 72473447 STARD10 T 0.06 2.03E-08 
11 rs114715767 72449727 ARAP1 G 0.05 1.09E-07 
21 rs67610389 43294820 PRDM15 A 0.03 1.20E-07 




Supplemental Table 4.6.  Top single variant results for African ancestry individuals, 
exome sequencing. 
Fructosamine (µmol/L) 
SNP Gene Chr A1/A2 P-value1 MAF Beta SE 
rs140658141 COL19A1 6 T/C 1.21E-07 0.003 31.39 5.93 
rs139579535 COL19A1 6 C/T 4.27E-07 0.005 25.62 5.07 
rs142200680 TTC16 9 T/C 1.36E-06 0.002 34.51 7.14 
rs139597330 FGL1 8 T/C 2.91E-06 0.005 24.22 5.18 
rs1480361 DOCK3 3 T/C 3.02E-06 0.003 -29.66 6.35 
rs149282922 SLC13A3 20 C/T 4.04E-06 0.003 28.22 6.12 
rs237025 SUMO4 6 G/A 5.12E-06 0.283 3.53 0.77 
rs149804703 TDRD7 9 G/A 8.94E-06 0.003 28.15 6.34 
rs73265846 PCDHGB3 5 C/T 1.43E-05 0.016 12.12 2.79 
rs77605839 FCHSD2 11 A/G 1.62E-05 0.028 9.50 2.20 
Glycated Albumin (%) 
SNP Gene Chr A1/A2 P-value1 MAF Beta SE 
rs115081997 DNAH7 2 A/G 6.03E-08 0.005 1.72 0.32 
rs149541658 SLC27A5 19 G/A 1.12E-07 0.009 1.35 0.26 
rs150448873 RNASE11 14 G/A 9.39E-07 0.002 2.34 0.48 
rs139597330 FGL1 8 T/C 5.04E-06 0.005 1.58 0.35 
rs184647368 UGT2B4 4 G/A 5.78E-06 0.003 1.99 0.44 
rs149804703 TDRD7 9 G/A 6.25E-06 0.003 1.91 0.42 
rs375699173 PLEC 8 C/T 7.41E-06 0.002 2.24 0.50 
rs201505339 FOSL2 2 A/G 9.96E-06 0.006 1.31 0.30 
rs11860488 CES5A 16 G/C 1.40E-05 0.422 0.21 0.05 
1Significant results are in bold: 0.05/(175,583 variants * 2 biomarkers)= 1.4x10-7 
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Supplemental Figure 4.1. Sample exclusions
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5.1 Abstract 
Introduction: Serum 1,5-anhydroglucitol (1,5-AG) is a measure of hyperglycemic 
excursions that is available as a clinical test to aid monitoring of glycemic control in 
persons with diabetes. Recent genome-wide association studies (GWAS) have identified 
several 1,5-AG associated common variants. Rare genetic variants may have large effects 
on the concentrations of biomarkers that are in clinical use. The association between rare 
coding variants and 1,5-AG concentrations measured with a targeted assay of 1,5-AG 
was investigated in individuals of European and African ancestries. 
Methods: Whole exome sequencing association analysis was performed on 1,5-AG 
among European ancestry (N=6,589) and African ancestry (N=2,309) participants 
without diagnosed diabetes in the Atherosclerosis Risk in Communities (ARIC) Study.  
Both single variant and gene-based tests were conducted. 
Results: Five variants representing 3 independent signals on chromosome 17 in 
SLC5A10 were associated with lower 1,5-AG levels of up to 10.38 µg/mL per allele (1,5-
AG range 3.4-32.8 µg/mL).  Two of these variants (rs61741107, p=8.85E-56, amino acid 
change: G>E; rs148178887, p=1.13E-36, amino acid change: N>I) with similar allele 
frequencies in the European (MAF=0.002 to 0.007) and African (MAF=0.0005 to 0.004) 
ancestry samples were rare, nonsynonymous, and predicted to be damaging or deleterious 
by multiple algorithms that predict deleteriousness.  Taken together, these three signals 
explained 6% of the variance in 1,5-AG.  Gene-based SKAT-O tests were significant for 
SLC5A10 in the European ancestry (p=5.13x10-64) and validated in the African ancestry 
(p=0.006) samples.  Significant common and low frequency variants were identified at 
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five other loci in or near MUC1, LCT, SI, MGAM, and SLC5A1 that also contain common 
1,5-AG associated variants.  
Conclusions: Several rare, protein-altering variants in individuals of European ancestry 
were associated with 1,5-AG concentrations and were validated in an African ancestry 
sample.  The large effect sizes for SLC5A10 variants and similar allele frequencies across 
populations without diabetes, along with the multiple independent signals are evidence of 
the important impact of SLC5A10 on serum 1,5-AG concentrations, and suggest 
SLC5A10 may code for an important transporter of 1,5-AG in the kidney.  This study 
helps to characterize the genetic architecture of 1,5-AG, an emerging diabetes biomarker, 
and may have implications for its clinical interpretation.  
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5.2 Introduction 
 1,5-andhydroglucitol (1,5-AG) is an emerging biomarker of glycemic control in 
type 2 diabetes. 1,5-AG is a monosaccharide consumed in food and maintained at high, 
constant levels in the blood under normoglycemic conditions through filtration by the 
kidney and reabsorption into the blood.  1,5-AG is the 1-deoxy form of glucose, and 
during hyperglycemic conditions (i.e., when glucose exceeds the renal threshold), glucose 
outcompetes 1,5-AG for reabsorption.  This causes 1,5-AG excretion in urine and hence 
lower levels in blood concentrations.1 In adults with diabetes, low 1,5-AG concentrations 
reflect glucose excursions over the previous 2-14 days,1,2  and are associated with 
microvascular and macrovascular disease.3,4,5 
In a recent genome-wide association study (GWAS), we identified seven variants 
at six loci associated with 1,5-AG among persons of European ancestry without 
diagnosed diabetes.6  Two of these variants were also found in a genetic screen of 1,5-AG 
measured as part of a large non-targeted metabolome panel among Europeans.7   These 
variants map in or near genes which are involved in carbohydrate metabolism (LCT, SI, 
MGAM, MGAM2) and glucose transport in the gut and kidney (SLC5A10, SLC50A1, 
SLC5A1).6  Interestingly, the majority of the variants are not associated with traditional 
measures of hyperglycemia such as fasting glucose and HbA1c.8,9  
While array-based analyses such as GWAS often capture common variants in 
linkage disequilibrium with the putative causal variants, they are not able to assess the 
impact of rare variants, nor are they designed to identify causal variants.  To investigate 
the association of rare, putatively damaging variants with 1,5-AG, and to further 
understand the genetic architecture of this biomarker, a whole-exome sequencing 
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association study of 1,5-AG concentrations was performed in the Atherosclerosis Risk In 




The ARIC Study is an ongoing, longitudinal cohort study initiated in 1987, when 
middle-aged adults were recruited from four communities in the U.S.: Forsyth, North 
Carolina; suburban Minneapolis, Minnesota; Washington County, Maryland and Jackson, 
Mississippi.  A total of 15,792 individuals attended the initial study visit (1987-1989), 
and subsequent visits occurred in 1990-1992 (visit 2), 1993-1995 (visit 3), 1996-1998 
(visit 4), and 2011-2013 (visit 5), and 2016-2017 (visit 6) with a seventh visit ongoing. 
The study protocol was approved by the relevant Institutional Review Boards, and all 
study participants provided written informed consent.10  For this study, data from 
individuals who attended visit 2 (N=14,348) was used.  
1,5-AG measurement 
 1,5-AG concentrations were measured using a colometric assay where 1,5-AG is 
oxidized to hydrogen peroxide (GlycoMark, Winston-Salem, NC) by the Roche Modular 
P800 system.  Serum was collected at visit 2 (1990-1992) and analyzed in 2012-2013. 
The interassay coefficient of variation was 4.8%.11   
Exome sequencing 
 DNA was extracted from blood primarily collected at visit 1.  All sequencing was 
performed as part of the CHARGE Consortium exome sequencing project at the Baylor 
College of Medicine Human Genome Sequencing Center (HGSC). Samples were bar-
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coded, pooled and sequenced using paired-end sequencing, run on the Illumina HiSeq 
2000 or 2500 platform (San Diego, CA), and exome capture performed with VCRome 
2.1 (NimbleGen, Inc., Madison, WI).  Sequence alignment was done using the Burrows-
Wheeler alignment12 tool with the Genome Reference Consortium Human Build 37 
reference sequence.  Aligned reads were then recalibrated using the Genome ANalysis 
ToolKit (GATK). Variant calling was done with the Mercury pipeline 
(https://www.hgsc.bcm.edu/content/mercury) in DNAnexus. VCF files were generated 
using the Atlas2 suite (Atlas-SNP and Atlas-Indel).   
Quality Control 
Standard quality control exclusion measures were implemented to ensure 
accurate, reliable results. Single nucleotide variants (SNVs) were excluded if they met 
any of the following criteria: posterior probability<0.95, variant read count <3, variant 
read ratio <0.25 or >0.75, strand bias >99% in single direction, total coverage<10 fold for 
SNVs (<30x for indels), outside exon capture regions, monomorphic variant, missing rate 
>20%, mappability score <0.8, mean depth coverage >500 fold, Hardy Weinberg 
Equilibrium p<5x10-6 in ancestry-specific groups.  Samples were excluded if they had 
>20% missing data or fell less than 6 standard deviations (SD) from mean read depth, 
more than 6 SD for singleton count, outside of 6 SD for heterozygote to homozygote ratio 
or transition to transversion (Ti/Tv) ratio.  After quality control, 2,556,859 SNVs and 
76,133 indels remained, and 7,810 European Ancestry individuals and 3,180 African 
Ancestry individuals remained. Individuals who did not attend visit 2 (N=594), were 
missing diabetes status (N=2), had diagnosed diabetes (self-reported physician diagnosis 
or use of diabetes medications; N=875), or missing 1,5-AG data at visit 2 (N=621; 
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Supplemental Figure 5.1) were also excluded.  In total, 6,589 European ancestry 
samples and 2,309 African ancestry samples were analyzed. 
Variant annotation and functional prediction 
 ANNOVAR8 and dbNSFP v2.0 (https://sites.google.com/site/jpopgen/dbNSFP) 
were used to annotate variants to genes and functional predictions using the GRCh37 
reference sequence and National Center for Biotechnology Information RefSeq.  
Functional annotation by several metrics predicted if a variant was expected to be 
damaging (an amino acid change which negatively impacts protein function) or 
deleterious (a variant which reduces fitness and is subject to purifying selection). SIFT 
score predicts if an amino acid change is likely to be damaging to protein function based 
on conservation (i.e., well conserved regions are assumed to be biologically important 
and thus variants in these regions are more likely to be damaging).13  A SIFT score <0.05 
was considered damaging.  Polyphen-2 flags amino acid changes that are predicted to be 
damaging based on the structure and function of a protein. Polyphen-2 score >0.957 was 
considered damaging, and a score between 0.453 and 0.965 was considered possibly 
damaging.14   GERP predicts substitutions that would have occurred if the region was not 
under selection and quantifies rate of substitutions that did not occur.15  A GERP score > 
2 was considered deleterious.  Finally, CADD aggregates annotations of allelic diversity, 
functionality, pathogenicity, disease severity, regulatory effects, complex trait 
associations, and known pathogenic variants into a score.16  A CADD score >15 was 
considered deleterious. In addition, the Bravo portal 
(https://bravo.sph.umich.edu/freeze5/hg38/) was used to obtain TOPMed and 1000 
Genomes allele frequencies (Freeze 5, including 463 million variants on 62784 
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individuals).  For each significant variant, the Genotype-Tissue Expression (GTEx) 
Project was searched for expression quantitative trait loci (eQTLs; 
https://www.gtexportal.org/home/).  
Single-variant tests 
 Genetic associations with 1,5-AG were analyzed using both single-variant and gene-
based tests using the R package SeqMeta.  All analyses were run separately by ancestry. 
1,5-AG values were winsorized at 1% and 99% to account for long tailed distributions. 
Single variant analyses were run as linear regressions controlling for age, sex, ARIC 
study center and significantly associated principal components (p<0.05; N=2 for 
European ancestry, 1 for African ancestry). To ensure our results were not driven by a 
very small number of individuals, variants with less than 10 copies of the minor allele 
(minimum MAF=10/(N*2)) were excluded. For the European ancestry sample 
MAF<0.008 (10/(6589*2)) was used and for the African ancestry sample MAF<0.002 
(10/(2309*2)) was used.  A Bonferroni correction to calculate a statistical significance 
threshold as 1.4x10-7 (0.05/121,052 variants) was used for European ancestry and 2.8x10-
7 (0.05/175,583 variants) was used for African ancestry.  Variance explained by 
individual variants was calculated as the difference between the coefficient of 
determination from the null model (the association between 1,5-AG and covariates) and a 
model adjusting for effect of the variant controlling for the same covariates. 
Gene-based tests 
 To augment power for situations where multiple rare variants affect association with 
a phenotype, the SKAT-O test was run, which aggregates variants into genes and tests for 
association between genes and phenotypes. SKAT-O combines a burden test, which has 
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greater power when variants are associated with the phenotype and in the same direction, 
with SKAT, a kernel based, variance components test, which has greater power when 
fewer variants are causal or affect risk in both directions. Genes with ≤1 variant per gene 
were excluded. Variants were not filtered by MAF in the main analysis.  Variants other 
than nonsynonymous, splicing, stop-gain, stop-loss, or frameshift were excluded from the 
association analyses.  Additionally, genes in which all variants used for the burden test 
together had a cumulative MAF<0.005 were excluded.  A Bonferroni correction was used 
to calculate a significance threshold: 4.0x10-6 (0.05/12,504 genes) for European ancestry 
and 3.3x10-5 (0.05/14,499 genes) for African ancestry.  Secondary analyses of SKAT and 
a T1 burden test (where all variants with MAF<0.01 were collapsed into a score for each 
gene) were also done. 
Conditional analyses 
 To determine if the single-variant results represent independent signals, the top 
variant (defined as most significant and most deleterious or damaging by GERP, SIFT, 
Polyphen2 and CADD) was conditioned on for each locus with multiple significant 
variants.  Secondary conditioning analyses were also performed on the most significant 
variant and the previous GWAS-identified variant. Regional association plots using 
LocusZoom (http://locuszoom.org/).17  were created to visualize the region prior to and 
after conditioning on the top variants. 
Variant association with diabetes 
 To determine if variants significantly associated with 1,5-AG also impact diabetes, 
the association between these variants and prevalent diabetes status was evaluated.  This 
analysis was performed for both diagnosed diabetes (self-reported physician diagnosis or 
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use of diabetes medications) and the combination of diagnosed diabetes and undiagnosed 
diabetes (defined as fasting glucose ≥126 mg/dL if fasting for ≥8 hours or non-fasting 




 There were 6,589 individuals in the European ancestry sample and 2,309 individuals 
in the African ancestry sample.  In both groups, over half were female, and mean age was 
56 to 57 years old.  1,5-AG levels were lower, and fructosamine, glycated albumin, 
fasting glucose and HbA1c were higher in the African ancestry sample as compared to 
the European ancestry sample. Study population characteristics are detailed in 
Supplemental Table 5.1. 
Single variant and gene-based analyses 
 In the European ancestry sample, 15 variants reached exome-wide significance for 
association with 1,5-AG in single variant testing (Table 5.1).  These variants are located 
in 6 loci on chromosomes 1, 2, 3, 7, 17, and 22, all of which were also identified in our 
previous GWAS of 1,5-AG concentrations.6  None of the African ancestry single variant 
or gene-based results were statistically significant.  
Rare, deleterious variants on chromosome 17  
 Four rare (MAF<0.007) and one low frequency (MAF=0.04) variants in the region 
of two overlapping genes on chromosome 17, SLC5A10 and FAM83G (Table 5.1) were 
associated with 1,5-AG. Of the four rare variants, two were nonsynonymous to SLC5A10 
and were highly significant (rs148178887, p=1.13x10-36 and rs61741107, p=8.85x10-56).  
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In addition, the effect sizes of these variants were large, approximately 10 µg/mL per risk 
allele, and explained 1.71% and 2.95% of the variance in 1,5-AG concentrations, 
respectively. The other two rare variants were intronic to SLC5A10 but nonsynonymous 
to FAM83G (rs200038747, p=1.69x10-13 and rs201046878, p=1.96x10-29).  The low 
frequency variant (rs117355297, p=3.85x10-26) was also found in the GWAS6 and was 
synonymous to SLC5A10. All four nonsynonymous variants were predicted to be 
damaging or deleterious by the prediction programs GERP, Polyphen-2, SIFT and 
CADD. In addition, the nonsynonymous variants resulted in amino acid changes which 
altered polarity and acidity (for example, rs61741107 resulted in a change from nonpolar 
glycine to acidic glutamic acid, and rs148178887 resulted in a change from polar 
asparagine to nonpoplar isoleucine).  Four variants were also nominally (p<0.05) 
associated with 1,5-AG in African ancestry individuals.  The gene-based SKAT-O test 
showed significance for SLC5A10 and FAM83G (Table 5.2). Secondary analyses of 
separate SKAT (p=2.8x10-55), T1 burden (p=2.5x10-114) and SKAT-O restricting variants 
to MAF<0.05 (p=5.1x10-64) tests also showed strong significance for SLC5A10 
(Supplemental tables 5.2-4).  
 To determine if the variants in this region were representing one signal in linkage 
disequilibrium or several independent signals, the nonsynonymous variants were 
conditioned on (Figure 5.1).  After conditioning on rs61741107, the variants 
rs148178887, rs201046878, rs200038747 and rs117355297 remained significant. After 
additionally conditioning on rs148178887, only rs117355297 remained significant. 
Further conditioning on the synonymous variant, rs117355297, produced no significant 
variants in this region.  Secondary conditioning on the previously identified GWAS 
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variant (rs117355297) showed the rare variants remained significant (p<2.7x10-14).  This 
suggests that these variants represent three independent, significant loci, which together 
explain 6% of the variance in 1,5-AG (Table 5.1).  GTEx did not show eQTLs for any of 
the chromosome 17 variants in diabetes-relevant tissue such as the kidney, liver or 
pancreas.  
 To further explore the rare variants in chromosome 17, they were evaluated for an 
association with diabetes. Of the variants representing the three significant signals on 
chromosome 17, none were significantly associated with diagnosed or 
diagnosed+undiagnosed diabetes status in either European or African ancestry samples 
(Supplemental Table 5.5).  In addition, mean 1,5-AG levels differed substantially 
between individuals with and without the chromosome 17 variants, while the mean 
values of other glycemic biomarkers did not. (Figure 5.2, Supplemental Figure 5.2).  
No individuals were homozygous for rs61741107 or rs148178887, but eight people were 
homozygous for rs117355297 (Supplemental Figure 5.3).  Four individuals had both 
rs61741107 and rs117355297 (mean 1,5-AG=2.8 µg/mL, SD=1.3 µg/mL), 23 had both 
rs148178887 and rs117355297 (mean 1,5-AG=9.5 µg/mL, SD=3.8 µg/mL), and two 
people were heterozygous for rs148178887 and homozygous for rs117355297 (mean 1,5-
AG=2.8 µg/mL, SD=0 µg/mL; Figure 5.2). 
Additional regions of interest 
 One common variant in MUC1 on chromosome 1 in linkage disequilibrium (LD) 
with a variant identified in our GWAS (rs9330264, r2=0.5) was associated with 1,5-AG, 
but the gene-based test was not significant. Neither the single variant or gene-based test 
was validated in the African ancestry sample. GTEx indicated possible eQTLs in 
 119 
diabetes-related tissues (liver: GBAP1 p=1.6x10-11, THBS3 p=2.5x10-6; pancreas: GBAP1 
p=3.3x10-25, THBS3 p=5.2x10-11, GBA p=6.3x10-8).   
 Five common variants in genes LCT, RAB3GAP1, R3HDM1, and UBXN4 were 
associated on chromosome 2 across a large region spanning 0.7 Mb. Three of these 
variants (rs961360, rs1050115, rs2304371) were in LD with the GWAS index variant, 
rs182549 (r2=0.27 to 0.35 in 1000 genomes phase3v5 European population).  Two of the 
five variants were nonsynonymous, one of which (rs961360) was predicted to be possibly 
damaging by Polyphen-2. The remaining three variants were synonymous and one was 
also associated in African ancestry individuals (rs1050115, p=0.01).  Conditional analysis 
on the top nonsynonymous variants revealed two distinct signals in this region 
(Supplemental Table 5.6).  The GWAS index variant was not present in this dataset and 
hence could not be conditioned on.  None of the genes in this region were associated with 
1,5-AG in the gene-based test. 
 One common variant on chromosome 3 in SI was associated with 1,5-AG in 
European ancestry individuals.  This variant is in near perfect LD with the GWAS index 
variant, rs9825346 (r2=0.98). It is a nonsynonymous variant, but was not predicted to be 
damaging or deleterious by any of the prediction programs and was not significant in 
African ancestry individuals.   
 One low-frequency (MAF=0.01) variant on chromosome 7 in MGAM was associated 
with 1,5-AG. This variant is not in LD with the GWAS index variant. It is 
nonsynonymous and predicted to be damaging or deleterious by GERP, Polyphen-2, 
SIFT and CADD, but was not significant in African ancestry individuals.  MGAM was 
associated with 1,5-AG in the gene-based test. 
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 Finally, two common variants in SLC5A1 were associated in this region.  Both 
variants were in near perfect LD with each other and the GWAS index variant, 
rs117086479 (r2=0.98 to 1). One variant was nonsynonymous (rs17683011) and the other 
was synonymous (rs17683448).  Neither had evidence for deleteriousness by any 
measure, and neither variant was associated with 1,5-AG in African ancestry individuals.  
SLC5A1 was significant in the gene-based test. 
 
5.5 Discussion 
 In this exome sequencing analysis, 15 variants were significantly associated with 
1,5-AG among people of European ancestry without diabetes, and four of these variants 
in two loci were validated in a sample of African ancestry individuals.  In addition, 4 
genes were associated with 1,5-AG among individuals of European ancestry, of which 
one (SLC5A10) validated in the African ancestry sample. 
 Both single variant and gene-based tests identified a region on chromosome 17 in or 
near SLC5A10 and the overlapping gene, FAM83G.  SLC5A10 is a glucose transporter 
exclusively expressed in the kidney,18  and is not known to also transport 1,5-AG. Our 
results, however, suggest SLC5A10 may be an important transporter of 1,5-AG. 
Conditional analysis identified multiple distinct signals in this locus.  Two of the variants 
identified (rs61741107 and rs148178887) were also found in a whole genome sequencing 
analysis of a metabolome panel,19  adding further evidence to the importance of this 
region in influencing 1,5-AG levels.  The effect sizes of most of the SLC5A10 variants 
are large. Given the distribution of 1,5-AG in this sample (in European ancestry: 3.4 to 
38.2 winsorized) having just one copy of the rs61741107 or rs148178887 allele would 
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result in a lowering of 1,5-AG by 10 µg/mL on average. Although no individuals in this 
dataset are homozygous for rs61741107 (1000 genomes European ancestry MAF = 
0.002) or rs148178887 (1000 genomes European ancestry MAF=0.005), the allele 
frequencies indicate that such individuals do exist in the population, and would have 
lowering of 1,5-AG levels of over 20 µg/mL on average. In addition, these effect sizes 
and allele frequencies were similar across ancestries.  The smaller p value for the T1 
gene-based test as compared to the SKAT test indicates that these variants impact 1,5-AG 
levels in the same direction.  The similar p-value for SKAT-O when restricting variants 
to MAF<0.05 indicates that the relevant variants are low-frequency and rare. 
 Many of the variants in this region are predicted to be damaging or deleterious by 
multiple programs.  SLC5A10 partially overlaps with FAM83G, which is expressed in the 
skin and esophagus (eQTLs; https://www.gtexportal.org/home/)18 .  It is not likely that 
variants in this region represent diabetes-related factors; neither gene is known to impact 
diabetes risk, fasting glucose or HbA1c. In addition, variants near SLC5A10 were not 
associated with diabetes status, and comparing individuals with and without variants in 
SLC5A10, multiple other measures of hyperglycemia were similar, while mean 1,5-AG 
differed substantially (Supplemental Figure 5.2). Given this evidence, it is likely that 
rs61741107 and rs148178887 represent putative causal variants for 1,5-AG in this region. 
 In addition, significant, common variants on chromosomes 1, 2, 3 and 22, and a low 
frequency variant on chromosome 7 were associated with 1,5-AG concentrations. These 
loci were all identified by our previous GWAS in the region near LCT/ UBXN4/ 
R3HDM1/ RAB3GAP1.  While several of the variants in this region are nonsynonymous, 
they were mainly not predicted to be damaging or deleterious, and the effect sizes are 
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relatively small, indicating a potentially more modest impact on 1,5-AG levels.  Other 
regions which were significantly associated among Europeans but not Africans including 
MGAM, SLC5A1 and SI.  Further studies are needed to confirm the role of rare variants in 
these regions in 1,5-AG. 
 There is currently debate about the utility of 1,5-AG as a useful biomarker of 
hyperglycemia in adults with diabetes. Prior to widespread use of any clinical test, it is 
important to identify limitations overall or for specific subpopulations.  Warren et al have 
shown that there is a proportion of individuals for whom 1,5-AG produces “false positive 
results”, i.e., where 1,5-AG concentrations are low while fasting glucose and 2-hour 
glucose levels are not elevated (manuscript in preparation). 20 Our work shows evidence 
of a strong genetic impact on 1,5-AG unrelated to diabetes, which may explain some of 
these findings. The likely nonglycemic genetic impact on 1,5-AG identified in this work 
is similar to previous findings in HbA1c, for which variants have been identified which 
impact HbA1c levels, but are not important mechanisms of glucose control.9,21,22 Our 
results may have implications for the overall utility of the biomarker independent of 
genetic characterization. 
 Exome sequencing has highlighted the role of SLC5A10 influencing 1,5-AG levels. 
This study has provided insight into the biology of this biomarker. Although these rare 
variants impact a smaller number of individuals than common variants, the large effect 
sizes would likely alter 1,5-AG levels in a sufficient manner to substantially impact its 




5.6 Tables and Figures  
 
Table 5.1. Significant1 1,5-AG (µg/mL) single SNP results in European ancestry sample, with validation in the African ancestry 
sample. 
          European ancestry (N=6,589) African ancestry (N=2,309) 




































rs61741107 SLC5A10 17 G/A NS G>E D,D,D,D 0.004 0.002 0 0.007 -9.31 (0.59) 8.85E-56 2.95 0.00057 -9.17 (3.95) 0.02 0.26 
rs148178887 SLC5A10 17 A/T NS N>I D,D,D,D 0.002 0.005 0 0.004 -10.38 (0.82) 1.13E-36 1.71 0.0027 -9.93 (2.80) 3.83E-04 0.36 
rs201046878 SLC5A10/ FAM83G6 17 G/A NS/I
5 R>W D,D,D,D 0.002 0.005 0.002 0.004 -8.33 (0.74) 1.96E-29 1.25 0.0027 -9.93 (2.80) 3.83E-04 0.33 
rs200038747 SLC5A10/ FAM83G6 17 C/T NS/I
5 R>Q D,D,D,D 0.002 0.001 0.005 0.002 -9.04 (1.23) 1.69E-13 0.61 0.004 0.25 (1.25) 0.84 0.09 
rs117355297 SLC5A10 17 C/T S -- T,NA,NA,D 0.022 0.05 0.001 0.04 -2.73 (0.26) 3.85E-26 1.37 0.005 -3.34 (1.12) 2.91E-03 0.2 
rs4072037 MUC1 1 C/T NS -- T,NA,NA,T 0.60 0.55 0.60 0.54 -0.49 (0.10) 3.74E-07 0.26 0.67 -0.22 (0.18) 0.21 0.1 
rs961360 R3HDM1 2 A/G NS M>V D,T,B/P,T 0.22 0.23 0.25 0.15 -0.80 (0.14) 7.82E-09 0.32 0.20 -0.41 (0.21) 0.05 0.3 
rs10445686 RAB3GAP1 2 A/G NS N>S D,T,B,T 0.14 0.19 0.02 0.13 -0.79 (0.14) 3.59E-08 0.35 0.03 0.21 (0.49) 0.66 0.04 
rs2304371 LCT 2 G/A S -- D,NA,NA,T 0.70 0.75 0.41 0.83 0.89 (0.13) 6.74E-12 0.49 0.45 0.39 (0.16) 0.02 0.13 
rs3739022 LCT 2 G/A S -- T,NA, NAT 0.16 0.15 0.22 0.10 -1.07 (0.17) 1.23E-10 0.51 0.21 -0.48 (0.20) 0.02 0.09 
rs1050115 UBXN4 2 A/G S -- T,NA,NA,T 0.17 0.21 0.17 0.15 -0.80 (0.14) 5.69E-09 0.35 0.14 -0.61 (0.24) 0.01 0.19 
rs9283633 SI 3 T/C NS T>A T,T,B,T 0.58 0.63 0.46 0.61 0.52 (0.10) 2.03E-07 0.33 0.48 0.29 (0.17) 0.09 0.17 
rs185053832 MGAM 7 C/A NS P>T D,D,D,D 0.006 0.01 0.001 0.01 -3.30 (0.49) 1.70E-11 0.63 0.0027 -1.26 (3.22) 0.69 0.01 
rs17683011 SLC5A1 22 A/G NS N>S T,T,B,T 0.04 0.06 0.003 0.07 -0.96 (0.19) 3.36E-07 0.31 0.02 -0.94 (0.66) 0.15 0.01 
rs17683448 SLC5A1 22 C/T S -- T,NA,NA,T 0.04 0.06 0.003 0.06 -1.14 (0.21) 5.26E-08 0.38 0.01 -0.97 (0.71) 0.17 0.02 
1Bonferroni corrected significance threshold = 4.1x10-7 (0.05/121,052 SNPs). 
2A2 is effect allele 
3NS=nonsynonymous, S=synonymous, I=intron 
4GERP, SIFT and CADD prediction: D=damaging, T=tolerated otherwise, Polyphen2 prediction: D=probably damaging, P=possibly damaging, B=benign 
 124 
5TGP=1000 genomes allele frequency for Eur (EA) and Afr (AA), AF=allele frequency 
6SLC5A10 and FAM83G are overlapping genes.  These variants are missense variants in FAM83G and intronic to SLC5A10. 
7Variants have minor allele count<10
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Table 5.2. Significant1 1,5-AG (µg/mL) gene-based results in European ancestry sample, 
validated in African ancestry sample. 
  European ancestry (N=6,589) African ancestry (N=2,309) 
Chr Gene P-value cMAF2 N SNPs P-value cMAF N SNPs 
17 SLC5A10 5.13E-64 0.04 58 0.006 0.29 28 
17 FAM83G 6.24E-17 0.06 56 0.39 0.34 36 
7 MGAM 8.20E-07 0.09 148 0.06 0.95 98 
22 SLC5A1 1.10E-06 0.23 48 0.21 0.07 15 
 
1Bonferroni corrected significance threshold = 4.0x10-6 (0.05/12,504 genes). 






















Figure 5.2. Distribution of 1,5-AG by chromosome 17 variants.1,2
 
11,5-AG is winsorized at 1% and 99% 
20: no copies of rs61741107, rs148178887 or rs117355297 minor alleles 
1a: 1 copy of rs117355297 minor allele 
1b: 1 copy of rs61741107 or rs148178887 minor alleles 
2a: 2 copies of rs117355297 minor alleles 
2b: 1 copy of rs61741107 or rs148178887 + 1 copy of rs117355297 minor allele 
3: 1 copy of rs61741107 or rs148178887 + 2 copies of rs117355297 minor allele 
 
   
















Female  55% 63% 57% 
Age 57 (5.6) 56 (5.7) 56.7 (5.7) 
Fructosamine (µmol/L)  227 (23) 238 (32) 230 (26) 
Glycated albumin (%) 12.6 (1.6) 13.6 (2.4) 12.9 (1.9) 
1,5-AG (µg/mL)  18.9 (5.8) 17.5 (5.8) 18.5 (5.8) 
HbA1c (%) 5.4 (0.52) 5.8 (0.86) 5.5 (0.64) 
Fasting glucose (mg/dL) 104 (17) 109 (26) 105 (20) 
ARIC study center    
     Jackson, Mississippi 0 90% 23% 
     Forsyth Co, North Carolina 25% 10% 21% 
     Washington Co, Maryland 30% 0 23% 
     Minneapolis suburbs, Minneapolis 45% 0 33% 




Supplemental Table 5.2. Association between chromosome 17 SNPs and diabetes status1 
 European ancestry (N=6,998) African ancestry (N=2,704) 
 Diagnosed diabetes  
(N=760 cases) 
Diagnosed and 
undiagnosed diabetes  
(N=351 cases) 
Diagnosed diabetes  
(N=644 cases) 
Diagnosed and 
undiagnosed diabetes  
(N=249 cases) 
 OR (95% CI) P-value OR (95% CI) 
P-
value OR (95% CI) 
P-
value OR (95% CI) 
P-
value 
rs617411072 0.85 (0.34, 2.12) 0.73 0.95 (0.49, 1.85) 0.88 -- -- -- -- 
rs148178887 0.34 (0.05, 2.50) 0.29 1.41 (0.63, 3.19) 0.41 1.61 (0.18, 14.55) 0.67 0.85 (0.09, 7.71) 0.89 
rs117355297 1.01 (0.69, 1.47) 0.98 1.03 (0.77, 1.34) 0.85 0.96 (0.33, 2.81) 0.95 1.06 (0.45, 2.51) 0.90 
1Diagnosed diabetes is defined as self-reported physician diagnosis or use of diabetes medications. Undiagnosed diabetes is defined as 
fasting glucose ≥126 mg/dL if fasting for ≥8 hours or fasting glucose >200 if not fasting for ≥8 hours). 
2Only two African ancestry individuals had rs61741107 alleles and thus was too colinear with diabetes to produce a regression 
estimate.
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Supplemental Table 5.3. Chromosome 2 significant results in European ancestry individuals, unconditioned and conditioned on top 
nonsynonymous variants. 




SNP Gene Position A1/A22 Effect AF Beta (SE) P-value
1 Beta (SE) P-value1 Beta (SE) P-value1 
rs961360 R3HDM1 136393658 A/G 0.15 -0.80 (0.14) 7.82E-09 -- -- -- -- 
rs2305165 R3HDM1 136409574 A/C 0.08 -0.85 (0.18) 1.86E-06 -0.98 (0.18) 5.89E-08 -- -- 
rs2304371 LCT 136561557 G/A 0.83 0.89 (0.13) 6.74E-12 0.79 (0.20) 1.2E-04 0.58 (0.21) 0.006 
rs3739022 LCT 136562472 G/A 0.10 -1.07 (0.17) 1.23E-10 -1.02 (0.17) 8.99E-10 -0.78 (0.22) 4.4E-04 
rs1050115 UBXN4 136511817 A/G 0.15 -0.80 (0.14) 5.69E-09 -0.53 (0.27) 0.05 -0.14 (0.28) 0.61 
rs10445686 RAB3GAP1 135893372 A/G 0.13 -0.79 (0.14) 3.59E-08 -0.35 (0.24) 0.14 -0.23 (0.24) 0.33 





































Supplemental Figure 5.2. Distribution of biomarkers by chromosome 17 variants.1,2 
 
 
1Biomarkers are winsorized at 1% and 99%. 











Chapter 6: Conclusions 
 
The goal of this work was to better understand the genetics of nontraditional 
glycemic biomarkers. We hypothesized that genetics would play a substantial role in 
fructosamine, glycated albumin and 1,5-AG and that both common and rare variants 
would be associated with these biomarkers.  The genetic variants could be diabetes-
related, adding insight to disease processes, or they may also be biomarker-specific, 
representing potential limitations of the biomarkers’ ability to accurately reflect blood 
glucose levels.  
 
6.1 Summary of Key Findings 
Heritability 
Heritability analyses showed that fructosamine, glycated albumin and 1,5-AG 
each have genetic variation. The proportion of variance in each biomarker (h2=0.44-0.55) 
due to genetics was similar to that of HbA1c (h2=0.34).  In addition, SNP-based 
heritability showed that common variants make up some of the heritability of these 
biomarkers but not all, leaving a likely role for rare variants. 
 
Fructosamine and Glycated Albumin Genome Wide Association 
GWAS analysis of fructosamine and glycated albumin identified a known 
diabetes variant in GCKR, significantly associated with 1.1% lower levels of percent 
glycated albumin per minor allele (p=5.3x10-9, variance explained=0.3%), and a likely 
nonglycemic variant in RCN3, significantly associated with 1.8% lower fructosamine per 
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minor allele (p=5.3x10-9, variance explained=0.6%).  In candidate SNP analysis, few 
established fasting glucose or HbA1c SNPs were associated with fructosamine or 
glycated albumin.  This work established a role for common variants impacting 
fructosamine and glycated albumin levels, and showed that these variants represent both 
glycemic and nonglycemic influences. 
 
Multivariate Phenotype Analysis 
In multivariate phenotype analysis, common variants in the UGT1A gene region 
were associated with a joint fructosamine-glycated albumin phenotype (p=3.18x10-8) that 
were not identified through analyses of either phenotype individually.  Single phenotype 
analysis showed a more significant association with fructosamine (p=6.04x10-6) than 
glycated albumin (p=0.72), implying that fructosamine may be driving the multivariate 
association.  The biology of this gene region is complex; it is involved in both diabetes 
and serum albumin, but the lack of significance with other glycemic biomarkers indicates 
the effect was more likely driven through albumin.  If this is the case, the UGT1A 
association with fructosamine would represent a nonglycemic genetic influence which 
could alter the clinical interpretation of fructosamine, but further evidence is required to 
better understand these findings. 
 
1,5-AG Sequencing 
Exome sequencing of 1,5-AG showed strong associations with rare and common 
variants in SLC5A10, a glucose transporter exclusively expressed in the kidney.  The 
effect sizes were large, approximately 10 µg/mL lower 1,5-AG levels per risk allele (1,5-
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AG range: 3.4-32.8 µg/mL) and seen in both the European American and African 
American samples.  These rare and common variants explained 6% of the total variance 
of 1,5-AG.  Conditional analysis and functional predictions showed strong evidence for 
an important impact of these variants on 1,5-AG levels.  The lack of association with 
diabetes and lack of change in other glycemic biomarkers (fructosamine, glycated 
albumin, fasting glucose, HbA1c) by genotype indicate that the SLC5A10 variants alter 
1,5-AG levels in a nonglycemic manner, which may affect the clinical use of 1,5-AG for 
diabetes monitoring. 
 
6.2 Strengths and Limitations 
Strengths and Limitations 
 A limitation of this work was the level of power to detect the association between 
genetic variants and nontraditional glycemic biomarkers. Because genetic studies perform 
millions of association tests (one for each genetic marker-phenotype combination), it is 
important to control for multiple comparison testing.  This is usually done using a strict 
Bonferroni threshold (0.05/number of tests). Thus, for the exome sequencing and 
multivariate phenotype analysis, we only considered variants above this threshold to be 
exome-wide or genome-wide significant. Increasing sample size is a common way to 
increase power.  While the sample size in European ancestry population was relatively 
large (N=approx.7,000) allowing for detection of variants in exome sequencing and 
multivariate phenotype as well as heritability, the smaller sample size in African ancestry 
population (N=approx. 2,000) prevented heritability analysis and likely impeded 
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detection of rare coding variants in exome sequencing and common variants in the 
multivariate phenotype analysis. 
 Another limitation of this dissertation was the lack of available additional cohorts 
in which to replicate these findings. Due to the Winner’s Curse impacting early GWAS, 
where significant variants found in one study but not in subsequent studies in other 
cohorts, replication in an additional cohort is necessary to rule out false positive findings 
from the discovery cohort.1  In addition, evaluating genetic associations in multiple 
populations can indicate if a variant is specific to a particular population or genetic 
ancestry, or if it generalizable across multiple populations. Replication was difficult for 
fructosamine, glycated albumin and 1,5-AG because they are not commonly collected in 
epidemiologic studies.  The lack of available replication cohorts impeded our ability to 
replicate our findings from exome sequencing and multivariate phenotype analyses. 
 Despite these limitations, a strength of this work was its novelty.  Few studies 
have examined the genetics of fructosamine, glycated albumin and 1,5-AG,2-4 and this 
work provided new insight into the genetic underpinnings of these biomarkers from 
heritability to associations.  In addition, the sample size among European Americans was 
substantial and provided sufficient power to detect rare variants associated with 1,5-AG. 
Comparison between variants associated with traditional and nontraditional glycemic 
biomarkers 
 One goal of this study was to compare newly discovered genetic variants 
associated with nontraditional glycemic biomarkers (fructosamine, glycated albumin and 
1,5-AG) to those found previously associated with traditional glycemic biomarkers 
(HbA1c and fasting glucose).  While we have done this comparison, it is important to 
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note that the studies which identified associations with fasting glucose and HbA1c were 
much larger and hence were better powered than the data we had available to find 
associations with fructosamine, glycated albumin and 1,5-AG.  This meant that we had 
some confidence that the variants unique to the nontraditional glycemic biomarkers were 
not associated with fasting glucose and HbA1c.  However, we could not rule out 
associations between nontraditional biomarkers and known traditional biomarker genetic 
variants that may be identified using larger sample sizes with more power to detect 
associations.  
Glycemic biomarkers in the nondiabetic range 
Fructosamine, glycated albumin and 1,5-AG have been proposed as 
complementary, and in some instances, alternative measures of hyperglycemia that can 
be used to monitor glycemic control in diabetes patients. In this study, however, these 
biomarkers were evaluated among individuals without diagnosed diabetes.  This was 
necessary to avoid the impact of treated diabetes on hyperglycemia levels, which would 
negatively bias associations between genetic variants and levels of glycemic biomarkers.  
However, this also has the effect of truncating the distribution of glycemic biomarkers so 
that fewer individuals with overt levels of hyperglycemia (extreme biomarker values) 
were captured.  Individuals with undiagnosed diabetes were retained in an attempt to 
capture some of the higher end of the distribution, but the number of people in that 
category was limited and their glucose levels did not reflect the highest levels in the 
distribution.  This is a common problem in other fields that study continuous markers of 
disease and some, such as blood pressure, simply implement a transformation for blood 
pressure values for individuals on treatment.  However, no such transformation is 
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commonly used in the diabetes field, and implementing one would be arbitrary, 
particularly for fructosamine, glycated albumin and 1,5-AG, which have not been 
extensively studied. The genetic variants which impact glucose levels at the nondiabetic 
range are not necessarily the same variants which impact glucose levels at the diabetic 
range.  This means that there may be diabetes-relevant variants associated with 
fructosamine, glycated albumin and 1,5-AG that were not able to be detected by this 
work, and we cannot be certain that the variants identified in this dissertation impact 
diabetes. 
 
6.3 Future Directions 
1,5-AG functional studies 
 The epidemiologic analyses in this dissertation provide evidence for putative 
causality of three variants in SLC5A10 on 1,5-AG levels, but causality, which is 
important for confirming drug or therapeutic targets, cannot be demonstrated without 
functional studies.  These are studies utilizing cell lines or animal models where the 
expression of SLC5A10 can be altered (for example, by CRISPER-Cas9 inactivation) and 
compared to cells or animals with unaltered SLC5A10 expression.  
More cohorts with biomarker data 
 To fully understand the genetics of fructosamine, glycated albumin and 1,5-AG, 
these biomarkers need to be studied in additional populations.  If they could be collected 
in samples which already have genotyping and sequencing data available, our findings 
could be evaluated for replication and the samples could be meta-analyzed, increasing the 
power to detect more associations at varying effect sizes.   
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Specifically, collecting biomarker data in African ancestry cohorts is important to 
determine if the genetic architecture is similar or different to that of European ancestry 
studies.  HbA1c is differentially impacted by genetic ancestry,5 and it is important to 
determine if fructosamine, glycated albumin and 1,5-AG also are altered differently by 
genetic ancestry.  This is particularly essential because average levels of all glycemic 
biomarkers differ by race, but the social construct of self-identified race does not 
necessarily reflect biologic genetic ancestry. Race and genetic ancestry are correlated and 
thus are often conflated, but while genetic ancestry solely reflects biology, race reflects 
both biology and environmental (i.e., social and cultural) factors.  Thus, differences in 
biomarker levels by race may be due to differences in environmental risk factors rather 
than differences in biology.  In lieu of race-specific clinical recommendations, Leong and 
Wheeler have proposed genotype-specific recommendations6 which would focus on 
differential allele frequencies and biology rather than risk factors associated with race.  
Whole-genome sequencing 
Whole-exome sequencing has the ability to capture rare variants in the coding 
region of the genome but is not designed to explain the noncoding region of the genome.  
While coding variants can impact the protein product of a gene and thus are potentially 
deleterious, this is not the only type of genetic variation which affects biology.  For 
example, variants in the noncoding region can affect gene regulation, controlling gene 
expression.  In the future, associations between whole-genome sequencing variations 




6.4 Public Health Significance 
The ultimate goal of this work was to improve treatment and care for those at risk 
for or diagnosed with type 2 diabetes.  An important basic step toward achieving this goal 
is to know if a person has diabetes or not, and if they do, how well it is managed.  This 
can be achieved by accurately reflecting hyperglycemia, which is measured by 
biomarkers. The shortcomings of current clinical biomarkers-- fasting glucose and 
HbA1c-- have led to increasing interest in alternatives or complimentary measures such 
as fructosamine, glycated albumin and 1,5-AG.  However, to use these nontraditional 
glycemic biomarkers clinically, it is necessary to understand their glycemic (glucose-
related) and nonglycemic (biomarker-limitations) determinants.  Genetics are a useful 
tool to elucidate these factors. 
Heritability analysis has shown that these biomarkers are under substantial genetic 
control, which has strengthened the case for the utility in understanding biomarker 
genetics to explain the variance in fructosamine, glycated albumin and 1,5-AG.   
Arguably the most clinically meaningful findings from this dissertation were the 
variants in SLC5A10 associated with 1,5-AG.  While these variants are rare, they explain 
6% of the variance in 1,5-AG, and the large effect sizes mean that an individual with a 
risk allele in this gene would have greatly reduced 1,5-AG levels: approximately 10 
µg/mL per risk allele, where the range of 1,5-AG in this sample was 3.4-32.8 µg/mL. If 
1,5-AG was used to measure glycemic control in such individuals, it would produce false 
positive results.  These could result in unnecessary medication use or higher doses than 
necessary, leading to hypoglycemia.  Our results may also suggest a new potential 
limitation of 1,5-AG in a clinical setting.   
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Alternatively, utility of 1,5-AG may differ by genotype, and should only be used 
in individuals without SLC5A10 risk alleles.  While personalized medicine is often 
thought of in respect to treatment options, it can also be implemented with diagnostics. 
Clinical genomics is becoming more prevalent, with large healthcare systems such as 
Geisinger Health System, Kaiser Permanente, and Veteran’s Health Administration all 
collecting genome-wide data on their patients.  Where such data exists, it would require 
little cost to have a message appear in the electronic medical record indicating if a 
patient’s genotype might impact the ability of 1,5-AG to reflect his or her glycemic peaks 
when a clinician orders a 1,5-AG test.  In such a setting, persons with nonglucose related 
1,5-AG genotypes may be flagged, and clinicians could tailor their choice of glucose tests 
accordingly. This is an important piece of the broader precision medicine initiative that 
can improve treatment by using existing data. 
The specific genetic variants associated with fructosamine and glycated albumin 
have been more difficult to uncover.  While the findings from this dissertation are not 
sufficient to impact the clinical use of fructosamine and glycated albumin, our results 
highlighted some potential limitations, and are a good first step towards additional 
understanding of how genetics may impact the clinical interpretation of these biomarkers. 
This dissertation has evaluated the role of genetics in nontraditional biomarkers of 
hyperglycemia – fructosamine, glycated albumin and 1,5-AG – contributing a piece to the 
large puzzle of improving health for those at risk for and diagnosed with type 2 diabetes.  
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